Correlation between copy number variation genes (focal) and selected clinical features
Uterine Corpus Endometrioid Carcinoma (Primary solid tumor)
22 February 2013  |  analyses__2013_02_22
Maintainer Information
Citation Information
doi:10.7908/C12J6940
Maintained by TCGA GDAC Team (Broad Institute/MD Anderson Cancer Center/Harvard Medical School)
Cite as Broad Institute TCGA Genome Data Analysis Center (2013): Correlation between copy number variation genes (focal) and selected clinical features. Broad Institute of MIT and Harvard. doi:10.7908/C12J6940
Overview
Introduction

This pipeline computes the correlation between significant copy number variation (cnv focal) genes and selected clinical features.

Summary

Testing the association between subtypes identified by 98 different clustering approaches and 5 clinical features across 447 patients, 156 significant findings detected with Q value < 0.25.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 1(1p35.2) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 2(1p34.2) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 3(1p22.3) mutation analysis'. These subtypes correlate to 'AGE'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 4(1q21.3) mutation analysis'. These subtypes correlate to 'AGE'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 5(1q22) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 6(1q42.3) mutation analysis'. These subtypes do not correlate to any clinical features.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 7(2p23.2) mutation analysis'. These subtypes correlate to 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 8(2q13) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 9(3p25.1) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 10(3p14.1) mutation analysis'. These subtypes correlate to 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 11(3q26.2) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 12(3q26.2) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 13(4p16.3) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 14(5p15.33) mutation analysis'. These subtypes correlate to 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 15(5q35.3) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 16(6p24.2) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 17(6q25.1) mutation analysis'. These subtypes correlate to 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 18(7q22.1) mutation analysis'. These subtypes correlate to 'Time to Death'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 19(8p11.21) mutation analysis'. These subtypes correlate to 'Time to Death' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 20(8q24.21) mutation analysis'. These subtypes correlate to 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 21(8q24.21) mutation analysis'. These subtypes correlate to 'HISTOLOGICAL.TYPE' and 'COMPLETENESS.OF.RESECTION'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 22(9p24.2) mutation analysis'. These subtypes correlate to 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 23(9q34.3) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 24(10q22.2) mutation analysis'. These subtypes do not correlate to any clinical features.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 25(11p11.2) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 26(11q13.2) mutation analysis'. These subtypes correlate to 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 27(12p12.1) mutation analysis'. These subtypes correlate to 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 28(12q13.11) mutation analysis'. These subtypes correlate to 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 29(12q13.2) mutation analysis'. These subtypes correlate to 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 30(13q34) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 31(14q24.3) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 32(14q32.33) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 33(16p11.2) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 34(17q11.2) mutation analysis'. These subtypes correlate to 'AGE',  'HISTOLOGICAL.TYPE', and 'COMPLETENESS.OF.RESECTION'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 35(17q12) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 36(17q25.1) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 37(18p11.31) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 38(18q11.2) mutation analysis'. These subtypes correlate to 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 39(19p13.2) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 40(19p13.11) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 41(19q12) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 42(20p13) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 43(20q11.21) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 44(20q13.12) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 45(20q13.33) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 46(22q12.2) mutation analysis'. These subtypes correlate to 'HISTOLOGICAL.TYPE' and 'COMPLETENESS.OF.RESECTION'.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 47(Xp11.23) mutation analysis'. These subtypes do not correlate to any clinical features.

  • 2 subtypes identified in current cancer cohort by 'Amp Peak 48(Xq28) mutation analysis'. These subtypes do not correlate to any clinical features.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 1(1p36.21) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 2(1p36.11) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 3(1q43) mutation analysis'. These subtypes do not correlate to any clinical features.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 4(2p25.3) mutation analysis'. These subtypes do not correlate to any clinical features.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 5(2q22.1) mutation analysis'. These subtypes correlate to 'Time to Death' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 6(2q37.3) mutation analysis'. These subtypes do not correlate to any clinical features.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 7(3p14.2) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 8(3q13.31) mutation analysis'. These subtypes correlate to 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 9(4p16.3) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 10(4p15.31) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 11(4q22.1) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 12(4q34.3) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 13(5q11.2) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 14(6q26) mutation analysis'. These subtypes correlate to 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 15(7p22.3) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 16(7q11.22) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 17(7q31.1) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 18(7q36.3) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 19(8p23.2) mutation analysis'. These subtypes correlate to 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 20(9p23) mutation analysis'. These subtypes correlate to 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 21(9q34.11) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 22(10q23.31) mutation analysis'. These subtypes correlate to 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 23(11p15.5) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 24(11q14.1) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 25(11q25) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 26(12q23.1) mutation analysis'. These subtypes correlate to 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 27(12q24.33) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 28(13q11) mutation analysis'. These subtypes correlate to 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 29(13q14.2) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 30(14q13.1) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 31(15q15.1) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 32(15q23) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 33(16p13.3) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 34(16q21) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 35(16q23.1) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 36(17p13.3) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 37(17p12) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 38(17p11.2) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 39(17q11.2) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 40(17q21.2) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 41(18q23) mutation analysis'. These subtypes correlate to 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 42(19p13.3) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 43(19p12) mutation analysis'. These subtypes correlate to 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 44(19q13.43) mutation analysis'. These subtypes correlate to 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 45(20p12.1) mutation analysis'. These subtypes do not correlate to any clinical features.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 46(22q11.1) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 47(22q12.1) mutation analysis'. These subtypes correlate to 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 48(22q13.31) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 49(22q13.32) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

  • 2 subtypes identified in current cancer cohort by 'Del Peak 50(Xp21.1) mutation analysis'. These subtypes correlate to 'AGE' and 'HISTOLOGICAL.TYPE'.

Results
Overview of the results

Table 1.  Get Full Table Overview of the association between subtypes identified by 98 different clustering approaches and 5 clinical features. Shown in the table are P values (Q values). Thresholded by Q value < 0.25, 156 significant findings detected.

Clinical
Features 		Time
to
Death 		AGE HISTOLOGICAL
TYPE 		RADIATIONS
RADIATION
REGIMENINDICATION 		COMPLETENESS
OF
RESECTION
Statistical Tests logrank test t-test Fisher's exact test Fisher's exact test Fisher's exact test
Amp Peak 1(1p35 2) 0.945
(1.00) 		0.000295
(0.102) 		3.23e-11
(1.39e-08) 		1
(1.00) 		0.872
(1.00)
Amp Peak 2(1p34 2) 0.648
(1.00) 		0.00012
(0.0427) 		6.05e-16
(2.78e-13) 		0.333
(1.00) 		0.145
(1.00)
Amp Peak 3(1p22 3) 0.732
(1.00) 		0.000314
(0.108) 		0.00305
(0.965) 		0.889
(1.00) 		0.502
(1.00)
Amp Peak 4(1q21 3) 0.173
(1.00) 		3.09e-06
(0.00119) 		0.00268
(0.852) 		0.603
(1.00) 		0.437
(1.00)
Amp Peak 5(1q22) 0.0389
(1.00) 		1.46e-07
(5.85e-05) 		1.6e-05
(0.00605) 		0.534
(1.00) 		0.256
(1.00)
Amp Peak 6(1q42 3) 0.267
(1.00) 		0.000978
(0.325) 		0.121
(1.00) 		0.6
(1.00) 		0.44
(1.00)
Amp Peak 7(2p23 2) 0.00563
(1.00) 		0.00406
(1.00) 		6.3e-12
(2.76e-09) 		0.0433
(1.00) 		0.887
(1.00)
Amp Peak 8(2q13) 0.0153
(1.00) 		0.000302
(0.104) 		2.52e-15
(1.15e-12) 		0.796
(1.00) 		0.246
(1.00)
Amp Peak 9(3p25 1) 0.403
(1.00) 		9.87e-05
(0.0352) 		3.04e-09
(1.27e-06) 		0.134
(1.00) 		0.766
(1.00)
Amp Peak 10(3p14 1) 0.00402
(1.00) 		0.00956
(1.00) 		0.000352
(0.12) 		0.0439
(1.00) 		0.377
(1.00)
Amp Peak 11(3q26 2) 0.151
(1.00) 		1.78e-09
(7.51e-07) 		1.21e-22
(5.83e-20) 		0.171
(1.00) 		0.182
(1.00)
Amp Peak 12(3q26 2) 0.0874
(1.00) 		1.93e-07
(7.73e-05) 		5.47e-23
(2.65e-20) 		0.246
(1.00) 		0.122
(1.00)
Amp Peak 13(4p16 3) 0.974
(1.00) 		8.4e-07
(0.000328) 		6.2e-13
(2.74e-10) 		0.718
(1.00) 		0.726
(1.00)
Amp Peak 14(5p15 33) 0.0477
(1.00) 		0.00587
(1.00) 		1.72e-15
(7.87e-13) 		0.658
(1.00) 		0.131
(1.00)
Amp Peak 15(5q35 3) 0.105
(1.00) 		0.00053
(0.179) 		1.16e-07
(4.69e-05) 		0.463
(1.00) 		0.544
(1.00)
Amp Peak 16(6p24 2) 0.824
(1.00) 		1.21e-06
(0.000469) 		4.15e-17
(1.94e-14) 		0.233
(1.00) 		0.822
(1.00)
Amp Peak 17(6q25 1) 0.824
(1.00) 		0.0101
(1.00) 		3.39e-05
(0.0124) 		0.658
(1.00) 		0.253
(1.00)
Amp Peak 18(7q22 1) 0.00054
(0.182) 		0.0487
(1.00) 		0.00497
(1.00) 		0.117
(1.00) 		0.512
(1.00)
Amp Peak 19(8p11 21) 1.59e-05
(0.00599) 		0.402
(1.00) 		1.36e-07
(5.49e-05) 		0.0417
(1.00) 		0.00477
(1.00)
Amp Peak 20(8q24 21) 0.00129
(0.424) 		0.548
(1.00) 		1.36e-12
(5.98e-10) 		0.042
(1.00) 		0.0262
(1.00)
Amp Peak 21(8q24 21) 0.00672
(1.00) 		0.238
(1.00) 		1.52e-13
(6.77e-11) 		0.0142
(1.00) 		0.000433
(0.147)
Amp Peak 22(9p24 2) 0.748
(1.00) 		0.00576
(1.00) 		1.1e-07
(4.45e-05) 		0.182
(1.00) 		0.436
(1.00)
Amp Peak 23(9q34 3) 0.0777
(1.00) 		0.000554
(0.186) 		2.26e-07
(9.04e-05) 		0.839
(1.00) 		0.327
(1.00)
Amp Peak 24(10q22 2) 0.185
(1.00) 		0.458
(1.00) 		0.045
(1.00) 		0.727
(1.00) 		0.39
(1.00)
Amp Peak 25(11p11 2) 0.0353
(1.00) 		0.000241
(0.0839) 		5.11e-08
(2.1e-05) 		0.851
(1.00) 		0.609
(1.00)
Amp Peak 26(11q13 2) 0.0908
(1.00) 		0.00119
(0.392) 		2.53e-07
(0.000101) 		1
(1.00) 		0.235
(1.00)
Amp Peak 27(12p12 1) 0.736
(1.00) 		0.51
(1.00) 		2.77e-07
(0.00011) 		0.664
(1.00) 		0.322
(1.00)
Amp Peak 28(12q13 11) 0.821
(1.00) 		0.832
(1.00) 		5.46e-07
(0.000215) 		0.192
(1.00) 		0.252
(1.00)
Amp Peak 29(12q13 2) 0.887
(1.00) 		0.076
(1.00) 		7.52e-07
(0.000295) 		0.0524
(1.00) 		0.066
(1.00)
Amp Peak 30(13q34) 0.671
(1.00) 		8.08e-07
(0.000316) 		9.08e-11
(3.9e-08) 		1
(1.00) 		0.125
(1.00)
Amp Peak 31(14q24 3) 0.495
(1.00) 		2.03e-05
(0.0076) 		1.62e-11
(7.01e-09) 		0.182
(1.00) 		0.774
(1.00)
Amp Peak 32(14q32 33) 0.175
(1.00) 		0.000239
(0.0838) 		1.45e-09
(6.13e-07) 		0.162
(1.00) 		0.109
(1.00)
Amp Peak 33(16p11 2) 0.0868
(1.00) 		0.00031
(0.107) 		8.05e-14
(3.61e-11) 		1
(1.00) 		0.0749
(1.00)
Amp Peak 34(17q11 2) 0.0432
(1.00) 		0.000251
(0.0873) 		4.04e-16
(1.86e-13) 		0.747
(1.00) 		0.000336
(0.115)
Amp Peak 35(17q12) 0.0605
(1.00) 		6.81e-05
(0.0246) 		1.86e-16
(8.63e-14) 		0.749
(1.00) 		0.0467
(1.00)
Amp Peak 36(17q25 1) 0.0505
(1.00) 		2.97e-05
(0.0109) 		2.56e-15
(1.16e-12) 		1
(1.00) 		0.263
(1.00)
Amp Peak 37(18p11 31) 0.494
(1.00) 		0.00028
(0.097) 		2.58e-18
(1.22e-15) 		0.0587
(1.00) 		0.00948
(1.00)
Amp Peak 38(18q11 2) 0.151
(1.00) 		0.0105
(1.00) 		8.76e-13
(3.87e-10) 		0.52
(1.00) 		0.076
(1.00)
Amp Peak 39(19p13 2) 0.65
(1.00) 		4.89e-11
(2.1e-08) 		1.19e-17
(5.58e-15) 		0.252
(1.00) 		0.795
(1.00)
Amp Peak 40(19p13 11) 0.594
(1.00) 		1.45e-10
(6.18e-08) 		1.86e-19
(8.8e-17) 		0.084
(1.00) 		0.306
(1.00)
Amp Peak 41(19q12) 0.00175
(0.565) 		3.71e-10
(1.58e-07) 		1.93e-34
(9.43e-32) 		0.687
(1.00) 		0.283
(1.00)
Amp Peak 42(20p13) 0.193
(1.00) 		5.29e-05
(0.0193) 		4.27e-12
(1.87e-09) 		0.24
(1.00) 		0.225
(1.00)
Amp Peak 43(20q11 21) 0.0393
(1.00) 		3.4e-07
(0.000135) 		5.23e-24
(2.54e-21) 		0.0687
(1.00) 		0.0632
(1.00)
Amp Peak 44(20q13 12) 0.305
(1.00) 		9.91e-08
(4.03e-05) 		1.1e-20
(5.25e-18) 		0.0166
(1.00) 		0.035
(1.00)
Amp Peak 45(20q13 33) 0.334
(1.00) 		3.68e-07
(0.000145) 		1.61e-16
(7.48e-14) 		0.00554
(1.00) 		0.0264
(1.00)
Amp Peak 46(22q12 2) 0.692
(1.00) 		0.00306
(0.968) 		5.75e-17
(2.67e-14) 		0.221
(1.00) 		0.000227
(0.0796)
Amp Peak 47(Xp11 23) 0.464
(1.00) 		0.226
(1.00) 		0.0265
(1.00) 		0.048
(1.00) 		0.311
(1.00)
Amp Peak 48(Xq28) 0.00822
(1.00) 		0.108
(1.00) 		0.00131
(0.428) 		1
(1.00) 		0.263
(1.00)
Del Peak 1(1p36 21) 0.45
(1.00) 		3.28e-05
(0.0121) 		1.05e-08
(4.36e-06) 		0.529
(1.00) 		0.367
(1.00)
Del Peak 2(1p36 11) 0.356
(1.00) 		3.68e-05
(0.0135) 		1.23e-11
(5.37e-09) 		0.76
(1.00) 		0.00882
(1.00)
Del Peak 3(1q43) 0.0272
(1.00) 		0.0221
(1.00) 		0.252
(1.00) 		0.109
(1.00) 		0.0337
(1.00)
Del Peak 4(2p25 3) 0.0264
(1.00) 		0.123
(1.00) 		0.00405
(1.00) 		0.0993
(1.00) 		0.191
(1.00)
Del Peak 5(2q22 1) 9.57e-09
(4e-06) 		0.00825
(1.00) 		2.41e-05
(0.00895) 		0.0181
(1.00) 		0.0019
(0.613)
Del Peak 6(2q37 3) 0.582
(1.00) 		0.000788
(0.262) 		0.0103
(1.00) 		0.366
(1.00) 		0.022
(1.00)
Del Peak 7(3p14 2) 0.81
(1.00) 		7.54e-05
(0.0272) 		6.23e-15
(2.83e-12) 		0.439
(1.00) 		0.446
(1.00)
Del Peak 8(3q13 31) 0.931
(1.00) 		0.00342
(1.00) 		6.98e-06
(0.00268) 		0.632
(1.00) 		0.924
(1.00)
Del Peak 9(4p16 3) 0.142
(1.00) 		0.000139
(0.049) 		2.78e-13
(1.24e-10) 		0.47
(1.00) 		0.597
(1.00)
Del Peak 10(4p15 31) 0.166
(1.00) 		8.27e-05
(0.0297) 		7.92e-12
(3.46e-09) 		0.11
(1.00) 		0.161
(1.00)
Del Peak 11(4q22 1) 0.00691
(1.00) 		1.58e-05
(0.00597) 		1.33e-22
(6.43e-20) 		0.218
(1.00) 		0.0485
(1.00)
Del Peak 12(4q34 3) 0.0279
(1.00) 		1.14e-05
(0.00433) 		2.59e-22
(1.24e-19) 		0.521
(1.00) 		0.0704
(1.00)
Del Peak 13(5q11 2) 0.0763
(1.00) 		6.49e-05
(0.0236) 		1.47e-21
(7.04e-19) 		0.588
(1.00) 		0.261
(1.00)
Del Peak 14(6q26) 0.268
(1.00) 		0.00493
(1.00) 		1.05e-08
(4.36e-06) 		0.848
(1.00) 		0.802
(1.00)
Del Peak 15(7p22 3) 0.0149
(1.00) 		2.51e-05
(0.0093) 		1.1e-13
(4.9e-11) 		0.541
(1.00) 		0.069
(1.00)
Del Peak 16(7q11 22) 0.557
(1.00) 		2.09e-05
(0.00778) 		9.54e-08
(3.9e-05) 		0.689
(1.00) 		0.426
(1.00)
Del Peak 17(7q31 1) 0.705
(1.00) 		3.68e-06
(0.00142) 		4.18e-16
(1.92e-13) 		0.588
(1.00) 		0.478
(1.00)
Del Peak 18(7q36 3) 0.569
(1.00) 		4.14e-08
(1.71e-05) 		2.21e-16
(1.02e-13) 		0.87
(1.00) 		0.235
(1.00)
Del Peak 19(8p23 2) 0.355
(1.00) 		0.00242
(0.773) 		1.08e-23
(5.26e-21) 		0.687
(1.00) 		0.0146
(1.00)
Del Peak 20(9p23) 0.409
(1.00) 		0.00078
(0.26) 		9.61e-11
(4.11e-08) 		0.333
(1.00) 		0.309
(1.00)
Del Peak 21(9q34 11) 0.319
(1.00) 		7.77e-10
(3.3e-07) 		6.56e-18
(3.09e-15) 		0.325
(1.00) 		0.306
(1.00)
Del Peak 22(10q23 31) 0.131
(1.00) 		0.00786
(1.00) 		1.9e-05
(0.00712) 		0.0779
(1.00) 		0.0761
(1.00)
Del Peak 23(11p15 5) 0.0121
(1.00) 		3.06e-08
(1.26e-05) 		2.7e-21
(1.29e-18) 		0.102
(1.00) 		0.0212
(1.00)
Del Peak 24(11q14 1) 0.0557
(1.00) 		2.66e-05
(0.00984) 		3.72e-14
(1.67e-11) 		0.52
(1.00) 		0.4
(1.00)
Del Peak 25(11q25) 0.0038
(1.00) 		0.000158
(0.0558) 		6.29e-15
(2.85e-12) 		0.032
(1.00) 		0.175
(1.00)
Del Peak 26(12q23 1) 0.0542
(1.00) 		0.00552
(1.00) 		4.05e-11
(1.75e-08) 		0.558
(1.00) 		0.0213
(1.00)
Del Peak 27(12q24 33) 0.11
(1.00) 		0.000116
(0.0413) 		4.36e-13
(1.94e-10) 		0.0843
(1.00) 		0.0323
(1.00)
Del Peak 28(13q11) 0.0112
(1.00) 		0.00108
(0.356) 		7.87e-10
(3.33e-07) 		0.311
(1.00) 		0.0483
(1.00)
Del Peak 29(13q14 2) 0.0408
(1.00) 		0.000327
(0.112) 		5.28e-05
(0.0193) 		0.159
(1.00) 		0.203
(1.00)
Del Peak 30(14q13 1) 0.00136
(0.444) 		0.000739
(0.247) 		9.68e-12
(4.22e-09) 		0.53
(1.00) 		0.899
(1.00)
Del Peak 31(15q15 1) 0.0386
(1.00) 		1.44e-08
(5.97e-06) 		6.83e-21
(3.26e-18) 		0.0658
(1.00) 		0.0207
(1.00)
Del Peak 32(15q23) 0.0577
(1.00) 		1.79e-05
(0.00674) 		7.29e-20
(3.46e-17) 		0.233
(1.00) 		0.433
(1.00)
Del Peak 33(16p13 3) 0.0339
(1.00) 		9.74e-08
(3.97e-05) 		1.02e-15
(4.69e-13) 		0.55
(1.00) 		0.0126
(1.00)
Del Peak 34(16q21) 0.052
(1.00) 		7.63e-09
(3.2e-06) 		1.85e-21
(8.88e-19) 		0.29
(1.00) 		0.122
(1.00)
Del Peak 35(16q23 1) 0.0634
(1.00) 		5.24e-08
(2.15e-05) 		3.42e-25
(1.67e-22) 		0.423
(1.00) 		0.00562
(1.00)
Del Peak 36(17p13 3) 0.116
(1.00) 		8.02e-05
(0.0289) 		4.59e-17
(2.14e-14) 		0.293
(1.00) 		0.223
(1.00)
Del Peak 37(17p12) 0.0757
(1.00) 		1.56e-07
(6.24e-05) 		4.91e-24
(2.39e-21) 		0.531
(1.00) 		0.669
(1.00)
Del Peak 38(17p11 2) 0.0439
(1.00) 		1.86e-06
(0.000721) 		2.42e-17
(1.14e-14) 		0.438
(1.00) 		0.778
(1.00)
Del Peak 39(17q11 2) 0.616
(1.00) 		8.22e-06
(0.00315) 		1.73e-10
(7.36e-08) 		0.174
(1.00) 		0.219
(1.00)
Del Peak 40(17q21 2) 0.145
(1.00) 		1.11e-05
(0.00425) 		4.62e-14
(2.07e-11) 		0.144
(1.00) 		0.113
(1.00)
Del Peak 41(18q23) 0.0107
(1.00) 		0.00195
(0.624) 		1.3e-14
(5.88e-12) 		0.00743
(1.00) 		0.0107
(1.00)
Del Peak 42(19p13 3) 0.0131
(1.00) 		1.81e-11
(7.83e-09) 		3.19e-46
(1.56e-43) 		0.345
(1.00) 		0.0041
(1.00)
Del Peak 43(19p12) 0.109
(1.00) 		0.0703
(1.00) 		1.35e-07
(5.45e-05) 		0.268
(1.00) 		0.301
(1.00)
Del Peak 44(19q13 43) 0.00165
(0.536) 		0.00213
(0.682) 		1.08e-14
(4.89e-12) 		1
(1.00) 		0.0438
(1.00)
Del Peak 45(20p12 1) 0.0867
(1.00) 		0.0531
(1.00) 		0.00111
(0.367) 		0.823
(1.00) 		0.158
(1.00)
Del Peak 46(22q11 1) 0.418
(1.00) 		9.75e-05
(0.0349) 		1.25e-05
(0.00473) 		0.0284
(1.00) 		0.787
(1.00)
Del Peak 47(22q12 1) 0.197
(1.00) 		0.00171
(0.553) 		2.09e-06
(0.000808) 		0.117
(1.00) 		0.665
(1.00)
Del Peak 48(22q13 31) 0.0141
(1.00) 		2.37e-08
(9.81e-06) 		4.51e-17
(2.11e-14) 		0.319
(1.00) 		0.811
(1.00)
Del Peak 49(22q13 32) 0.0126
(1.00) 		5.33e-07
(0.00021) 		4.69e-18
(2.21e-15) 		0.0877
(1.00) 		0.609
(1.00)
Del Peak 50(Xp21 1) 0.00348
(1.00) 		0.000158
(0.0558) 		1.32e-12
(5.83e-10) 		0.55
(1.00) 		0.106
(1.00)
Clustering Approach #1: 'Amp Peak 1(1p35.2) mutation analysis'

Table S1.  Description of clustering approach #1: 'Amp Peak 1(1p35.2) mutation analysis'

Cluster Labels AMP PEAK 1(1P35.2) MUTATED AMP PEAK 1(1P35.2) WILD-TYPE
Number of samples 41 406
'Amp Peak 1(1p35.2) mutation analysis' versus 'AGE'

P value = 0.000295 (t-test), Q value = 0.1

Table S2.  Clustering Approach #1: 'Amp Peak 1(1p35.2) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
AMP PEAK 1(1P35.2) MUTATED 41 68.7 (8.7)
AMP PEAK 1(1P35.2) WILD-TYPE 405 63.1 (11.4)

Figure S1.  Get High-res Image Clustering Approach #1: 'Amp Peak 1(1p35.2) mutation analysis' versus Clinical Feature #2: 'AGE'

'Amp Peak 1(1p35.2) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 3.23e-11 (Fisher's exact test), Q value = 1.4e-08

Table S3.  Clustering Approach #1: 'Amp Peak 1(1p35.2) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
AMP PEAK 1(1P35.2) MUTATED 13 4 24
AMP PEAK 1(1P35.2) WILD-TYPE 337 14 55

Figure S2.  Get High-res Image Clustering Approach #1: 'Amp Peak 1(1p35.2) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #2: 'Amp Peak 2(1p34.2) mutation analysis'

Table S4.  Description of clustering approach #2: 'Amp Peak 2(1p34.2) mutation analysis'

Cluster Labels AMP PEAK 2(1P34.2) MUTATED AMP PEAK 2(1P34.2) WILD-TYPE
Number of samples 52 395
'Amp Peak 2(1p34.2) mutation analysis' versus 'AGE'

P value = 0.00012 (t-test), Q value = 0.043

Table S5.  Clustering Approach #2: 'Amp Peak 2(1p34.2) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
AMP PEAK 2(1P34.2) MUTATED 52 68.9 (9.8)
AMP PEAK 2(1P34.2) WILD-TYPE 394 62.9 (11.3)

Figure S3.  Get High-res Image Clustering Approach #2: 'Amp Peak 2(1p34.2) mutation analysis' versus Clinical Feature #2: 'AGE'

'Amp Peak 2(1p34.2) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 6.05e-16 (Fisher's exact test), Q value = 2.8e-13

Table S6.  Clustering Approach #2: 'Amp Peak 2(1p34.2) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
AMP PEAK 2(1P34.2) MUTATED 15 6 31
AMP PEAK 2(1P34.2) WILD-TYPE 335 12 48

Figure S4.  Get High-res Image Clustering Approach #2: 'Amp Peak 2(1p34.2) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #3: 'Amp Peak 3(1p22.3) mutation analysis'

Table S7.  Description of clustering approach #3: 'Amp Peak 3(1p22.3) mutation analysis'

Cluster Labels AMP PEAK 3(1P22.3) MUTATED AMP PEAK 3(1P22.3) WILD-TYPE
Number of samples 74 373
'Amp Peak 3(1p22.3) mutation analysis' versus 'AGE'

P value = 0.000314 (t-test), Q value = 0.11

Table S8.  Clustering Approach #3: 'Amp Peak 3(1p22.3) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
AMP PEAK 3(1P22.3) MUTATED 74 67.6 (10.1)
AMP PEAK 3(1P22.3) WILD-TYPE 372 62.8 (11.3)

Figure S5.  Get High-res Image Clustering Approach #3: 'Amp Peak 3(1p22.3) mutation analysis' versus Clinical Feature #2: 'AGE'

Clustering Approach #4: 'Amp Peak 4(1q21.3) mutation analysis'

Table S9.  Description of clustering approach #4: 'Amp Peak 4(1q21.3) mutation analysis'

Cluster Labels AMP PEAK 4(1Q21.3) MUTATED AMP PEAK 4(1Q21.3) WILD-TYPE
Number of samples 194 253
'Amp Peak 4(1q21.3) mutation analysis' versus 'AGE'

P value = 3.09e-06 (t-test), Q value = 0.0012

Table S10.  Clustering Approach #4: 'Amp Peak 4(1q21.3) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
AMP PEAK 4(1Q21.3) MUTATED 194 66.4 (10.5)
AMP PEAK 4(1Q21.3) WILD-TYPE 252 61.4 (11.4)

Figure S6.  Get High-res Image Clustering Approach #4: 'Amp Peak 4(1q21.3) mutation analysis' versus Clinical Feature #2: 'AGE'

Clustering Approach #5: 'Amp Peak 5(1q22) mutation analysis'

Table S11.  Description of clustering approach #5: 'Amp Peak 5(1q22) mutation analysis'

Cluster Labels AMP PEAK 5(1Q22) MUTATED AMP PEAK 5(1Q22) WILD-TYPE
Number of samples 206 241
'Amp Peak 5(1q22) mutation analysis' versus 'AGE'

P value = 1.46e-07 (t-test), Q value = 5.9e-05

Table S12.  Clustering Approach #5: 'Amp Peak 5(1q22) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
AMP PEAK 5(1Q22) MUTATED 206 66.5 (10.5)
AMP PEAK 5(1Q22) WILD-TYPE 240 61.0 (11.3)

Figure S7.  Get High-res Image Clustering Approach #5: 'Amp Peak 5(1q22) mutation analysis' versus Clinical Feature #2: 'AGE'

'Amp Peak 5(1q22) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 1.6e-05 (Fisher's exact test), Q value = 0.006

Table S13.  Clustering Approach #5: 'Amp Peak 5(1q22) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
AMP PEAK 5(1Q22) MUTATED 143 8 55
AMP PEAK 5(1Q22) WILD-TYPE 207 10 24

Figure S8.  Get High-res Image Clustering Approach #5: 'Amp Peak 5(1q22) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #6: 'Amp Peak 6(1q42.3) mutation analysis'

Table S14.  Description of clustering approach #6: 'Amp Peak 6(1q42.3) mutation analysis'

Cluster Labels AMP PEAK 6(1Q42.3) MUTATED AMP PEAK 6(1Q42.3) WILD-TYPE
Number of samples 184 263
Clustering Approach #7: 'Amp Peak 7(2p23.2) mutation analysis'

Table S15.  Description of clustering approach #7: 'Amp Peak 7(2p23.2) mutation analysis'

Cluster Labels AMP PEAK 7(2P23.2) MUTATED AMP PEAK 7(2P23.2) WILD-TYPE
Number of samples 94 353
'Amp Peak 7(2p23.2) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 6.3e-12 (Fisher's exact test), Q value = 2.8e-09

Table S16.  Clustering Approach #7: 'Amp Peak 7(2p23.2) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
AMP PEAK 7(2P23.2) MUTATED 47 7 40
AMP PEAK 7(2P23.2) WILD-TYPE 303 11 39

Figure S9.  Get High-res Image Clustering Approach #7: 'Amp Peak 7(2p23.2) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #8: 'Amp Peak 8(2q13) mutation analysis'

Table S17.  Description of clustering approach #8: 'Amp Peak 8(2q13) mutation analysis'

Cluster Labels AMP PEAK 8(2Q13) MUTATED AMP PEAK 8(2Q13) WILD-TYPE
Number of samples 89 358
'Amp Peak 8(2q13) mutation analysis' versus 'AGE'

P value = 0.000302 (t-test), Q value = 0.1

Table S18.  Clustering Approach #8: 'Amp Peak 8(2q13) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
AMP PEAK 8(2Q13) MUTATED 88 67.0 (9.1)
AMP PEAK 8(2Q13) WILD-TYPE 358 62.7 (11.6)

Figure S10.  Get High-res Image Clustering Approach #8: 'Amp Peak 8(2q13) mutation analysis' versus Clinical Feature #2: 'AGE'

'Amp Peak 8(2q13) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 2.52e-15 (Fisher's exact test), Q value = 1.1e-12

Table S19.  Clustering Approach #8: 'Amp Peak 8(2q13) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
AMP PEAK 8(2Q13) MUTATED 41 4 44
AMP PEAK 8(2Q13) WILD-TYPE 309 14 35

Figure S11.  Get High-res Image Clustering Approach #8: 'Amp Peak 8(2q13) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #9: 'Amp Peak 9(3p25.1) mutation analysis'

Table S20.  Description of clustering approach #9: 'Amp Peak 9(3p25.1) mutation analysis'

Cluster Labels AMP PEAK 9(3P25.1) MUTATED AMP PEAK 9(3P25.1) WILD-TYPE
Number of samples 61 386
'Amp Peak 9(3p25.1) mutation analysis' versus 'AGE'

P value = 9.87e-05 (t-test), Q value = 0.035

Table S21.  Clustering Approach #9: 'Amp Peak 9(3p25.1) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
AMP PEAK 9(3P25.1) MUTATED 61 68.9 (10.9)
AMP PEAK 9(3P25.1) WILD-TYPE 385 62.7 (11.1)

Figure S12.  Get High-res Image Clustering Approach #9: 'Amp Peak 9(3p25.1) mutation analysis' versus Clinical Feature #2: 'AGE'

'Amp Peak 9(3p25.1) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 3.04e-09 (Fisher's exact test), Q value = 1.3e-06

Table S22.  Clustering Approach #9: 'Amp Peak 9(3p25.1) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
AMP PEAK 9(3P25.1) MUTATED 30 1 30
AMP PEAK 9(3P25.1) WILD-TYPE 320 17 49

Figure S13.  Get High-res Image Clustering Approach #9: 'Amp Peak 9(3p25.1) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #10: 'Amp Peak 10(3p14.1) mutation analysis'

Table S23.  Description of clustering approach #10: 'Amp Peak 10(3p14.1) mutation analysis'

Cluster Labels AMP PEAK 10(3P14.1) MUTATED AMP PEAK 10(3P14.1) WILD-TYPE
Number of samples 48 399
'Amp Peak 10(3p14.1) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 0.000352 (Fisher's exact test), Q value = 0.12

Table S24.  Clustering Approach #10: 'Amp Peak 10(3p14.1) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
AMP PEAK 10(3P14.1) MUTATED 27 2 19
AMP PEAK 10(3P14.1) WILD-TYPE 323 16 60

Figure S14.  Get High-res Image Clustering Approach #10: 'Amp Peak 10(3p14.1) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #11: 'Amp Peak 11(3q26.2) mutation analysis'

Table S25.  Description of clustering approach #11: 'Amp Peak 11(3q26.2) mutation analysis'

Cluster Labels AMP PEAK 11(3Q26.2) MUTATED AMP PEAK 11(3Q26.2) WILD-TYPE
Number of samples 129 318
'Amp Peak 11(3q26.2) mutation analysis' versus 'AGE'

P value = 1.78e-09 (t-test), Q value = 7.5e-07

Table S26.  Clustering Approach #11: 'Amp Peak 11(3q26.2) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
AMP PEAK 11(3Q26.2) MUTATED 129 68.2 (9.5)
AMP PEAK 11(3Q26.2) WILD-TYPE 317 61.7 (11.4)

Figure S15.  Get High-res Image Clustering Approach #11: 'Amp Peak 11(3q26.2) mutation analysis' versus Clinical Feature #2: 'AGE'

'Amp Peak 11(3q26.2) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 1.21e-22 (Fisher's exact test), Q value = 5.8e-20

Table S27.  Clustering Approach #11: 'Amp Peak 11(3q26.2) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
AMP PEAK 11(3Q26.2) MUTATED 62 7 60
AMP PEAK 11(3Q26.2) WILD-TYPE 288 11 19

Figure S16.  Get High-res Image Clustering Approach #11: 'Amp Peak 11(3q26.2) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #12: 'Amp Peak 12(3q26.2) mutation analysis'

Table S28.  Description of clustering approach #12: 'Amp Peak 12(3q26.2) mutation analysis'

Cluster Labels AMP PEAK 12(3Q26.2) MUTATED AMP PEAK 12(3Q26.2) WILD-TYPE
Number of samples 122 325
'Amp Peak 12(3q26.2) mutation analysis' versus 'AGE'

P value = 1.93e-07 (t-test), Q value = 7.7e-05

Table S29.  Clustering Approach #12: 'Amp Peak 12(3q26.2) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
AMP PEAK 12(3Q26.2) MUTATED 122 67.7 (9.5)
AMP PEAK 12(3Q26.2) WILD-TYPE 324 62.0 (11.5)

Figure S17.  Get High-res Image Clustering Approach #12: 'Amp Peak 12(3q26.2) mutation analysis' versus Clinical Feature #2: 'AGE'

'Amp Peak 12(3q26.2) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 5.47e-23 (Fisher's exact test), Q value = 2.6e-20

Table S30.  Clustering Approach #12: 'Amp Peak 12(3q26.2) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
AMP PEAK 12(3Q26.2) MUTATED 57 6 59
AMP PEAK 12(3Q26.2) WILD-TYPE 293 12 20

Figure S18.  Get High-res Image Clustering Approach #12: 'Amp Peak 12(3q26.2) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #13: 'Amp Peak 13(4p16.3) mutation analysis'

Table S31.  Description of clustering approach #13: 'Amp Peak 13(4p16.3) mutation analysis'

Cluster Labels AMP PEAK 13(4P16.3) MUTATED AMP PEAK 13(4P16.3) WILD-TYPE
Number of samples 40 407
'Amp Peak 13(4p16.3) mutation analysis' versus 'AGE'

P value = 8.4e-07 (t-test), Q value = 0.00033

Table S32.  Clustering Approach #13: 'Amp Peak 13(4p16.3) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
AMP PEAK 13(4P16.3) MUTATED 40 70.9 (8.4)
AMP PEAK 13(4P16.3) WILD-TYPE 406 62.9 (11.3)

Figure S19.  Get High-res Image Clustering Approach #13: 'Amp Peak 13(4p16.3) mutation analysis' versus Clinical Feature #2: 'AGE'

'Amp Peak 13(4p16.3) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 6.2e-13 (Fisher's exact test), Q value = 2.7e-10

Table S33.  Clustering Approach #13: 'Amp Peak 13(4p16.3) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
AMP PEAK 13(4P16.3) MUTATED 12 1 27
AMP PEAK 13(4P16.3) WILD-TYPE 338 17 52

Figure S20.  Get High-res Image Clustering Approach #13: 'Amp Peak 13(4p16.3) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #14: 'Amp Peak 14(5p15.33) mutation analysis'

Table S34.  Description of clustering approach #14: 'Amp Peak 14(5p15.33) mutation analysis'

Cluster Labels AMP PEAK 14(5P15.33) MUTATED AMP PEAK 14(5P15.33) WILD-TYPE
Number of samples 64 383
'Amp Peak 14(5p15.33) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 1.72e-15 (Fisher's exact test), Q value = 7.9e-13

Table S35.  Clustering Approach #14: 'Amp Peak 14(5p15.33) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
AMP PEAK 14(5P15.33) MUTATED 24 3 37
AMP PEAK 14(5P15.33) WILD-TYPE 326 15 42

Figure S21.  Get High-res Image Clustering Approach #14: 'Amp Peak 14(5p15.33) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #15: 'Amp Peak 15(5q35.3) mutation analysis'

Table S36.  Description of clustering approach #15: 'Amp Peak 15(5q35.3) mutation analysis'

Cluster Labels AMP PEAK 15(5Q35.3) MUTATED AMP PEAK 15(5Q35.3) WILD-TYPE
Number of samples 39 408
'Amp Peak 15(5q35.3) mutation analysis' versus 'AGE'

P value = 0.00053 (t-test), Q value = 0.18

Table S37.  Clustering Approach #15: 'Amp Peak 15(5q35.3) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
AMP PEAK 15(5Q35.3) MUTATED 39 69.7 (10.7)
AMP PEAK 15(5Q35.3) WILD-TYPE 407 63.0 (11.1)

Figure S22.  Get High-res Image Clustering Approach #15: 'Amp Peak 15(5q35.3) mutation analysis' versus Clinical Feature #2: 'AGE'

'Amp Peak 15(5q35.3) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 1.16e-07 (Fisher's exact test), Q value = 4.7e-05

Table S38.  Clustering Approach #15: 'Amp Peak 15(5q35.3) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
AMP PEAK 15(5Q35.3) MUTATED 16 2 21
AMP PEAK 15(5Q35.3) WILD-TYPE 334 16 58

Figure S23.  Get High-res Image Clustering Approach #15: 'Amp Peak 15(5q35.3) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #16: 'Amp Peak 16(6p24.2) mutation analysis'

Table S39.  Description of clustering approach #16: 'Amp Peak 16(6p24.2) mutation analysis'

Cluster Labels AMP PEAK 16(6P24.2) MUTATED AMP PEAK 16(6P24.2) WILD-TYPE
Number of samples 83 364
'Amp Peak 16(6p24.2) mutation analysis' versus 'AGE'

P value = 1.21e-06 (t-test), Q value = 0.00047

Table S40.  Clustering Approach #16: 'Amp Peak 16(6p24.2) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
AMP PEAK 16(6P24.2) MUTATED 83 68.7 (9.9)
AMP PEAK 16(6P24.2) WILD-TYPE 363 62.4 (11.2)

Figure S24.  Get High-res Image Clustering Approach #16: 'Amp Peak 16(6p24.2) mutation analysis' versus Clinical Feature #2: 'AGE'

'Amp Peak 16(6p24.2) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 4.15e-17 (Fisher's exact test), Q value = 1.9e-14

Table S41.  Clustering Approach #16: 'Amp Peak 16(6p24.2) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
AMP PEAK 16(6P24.2) MUTATED 35 4 44
AMP PEAK 16(6P24.2) WILD-TYPE 315 14 35

Figure S25.  Get High-res Image Clustering Approach #16: 'Amp Peak 16(6p24.2) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #17: 'Amp Peak 17(6q25.1) mutation analysis'

Table S42.  Description of clustering approach #17: 'Amp Peak 17(6q25.1) mutation analysis'

Cluster Labels AMP PEAK 17(6Q25.1) MUTATED AMP PEAK 17(6Q25.1) WILD-TYPE
Number of samples 64 383
'Amp Peak 17(6q25.1) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 3.39e-05 (Fisher's exact test), Q value = 0.012

Table S43.  Clustering Approach #17: 'Amp Peak 17(6q25.1) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
AMP PEAK 17(6Q25.1) MUTATED 37 2 25
AMP PEAK 17(6Q25.1) WILD-TYPE 313 16 54

Figure S26.  Get High-res Image Clustering Approach #17: 'Amp Peak 17(6q25.1) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #18: 'Amp Peak 18(7q22.1) mutation analysis'

Table S44.  Description of clustering approach #18: 'Amp Peak 18(7q22.1) mutation analysis'

Cluster Labels AMP PEAK 18(7Q22.1) MUTATED AMP PEAK 18(7Q22.1) WILD-TYPE
Number of samples 70 377
'Amp Peak 18(7q22.1) mutation analysis' versus 'Time to Death'

P value = 0.00054 (logrank test), Q value = 0.18

Table S45.  Clustering Approach #18: 'Amp Peak 18(7q22.1) mutation analysis' versus Clinical Feature #1: 'Time to Death'

nPatients nDeath Duration Range (Median), Month
ALL 442 41 0.0 - 187.1 (15.9)
AMP PEAK 18(7Q22.1) MUTATED 68 13 0.0 - 113.2 (13.1)
AMP PEAK 18(7Q22.1) WILD-TYPE 374 28 0.1 - 187.1 (16.4)

Figure S27.  Get High-res Image Clustering Approach #18: 'Amp Peak 18(7q22.1) mutation analysis' versus Clinical Feature #1: 'Time to Death'

Clustering Approach #19: 'Amp Peak 19(8p11.21) mutation analysis'

Table S46.  Description of clustering approach #19: 'Amp Peak 19(8p11.21) mutation analysis'

Cluster Labels AMP PEAK 19(8P11.21) MUTATED AMP PEAK 19(8P11.21) WILD-TYPE
Number of samples 131 316
'Amp Peak 19(8p11.21) mutation analysis' versus 'Time to Death'

P value = 1.59e-05 (logrank test), Q value = 0.006

Table S47.  Clustering Approach #19: 'Amp Peak 19(8p11.21) mutation analysis' versus Clinical Feature #1: 'Time to Death'

nPatients nDeath Duration Range (Median), Month
ALL 442 41 0.0 - 187.1 (15.9)
AMP PEAK 19(8P11.21) MUTATED 129 22 0.0 - 113.2 (11.5)
AMP PEAK 19(8P11.21) WILD-TYPE 313 19 0.0 - 187.1 (16.9)

Figure S28.  Get High-res Image Clustering Approach #19: 'Amp Peak 19(8p11.21) mutation analysis' versus Clinical Feature #1: 'Time to Death'

'Amp Peak 19(8p11.21) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 1.36e-07 (Fisher's exact test), Q value = 5.5e-05

Table S48.  Clustering Approach #19: 'Amp Peak 19(8p11.21) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
AMP PEAK 19(8P11.21) MUTATED 81 6 44
AMP PEAK 19(8P11.21) WILD-TYPE 269 12 35

Figure S29.  Get High-res Image Clustering Approach #19: 'Amp Peak 19(8p11.21) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #20: 'Amp Peak 20(8q24.21) mutation analysis'

Table S49.  Description of clustering approach #20: 'Amp Peak 20(8q24.21) mutation analysis'

Cluster Labels AMP PEAK 20(8Q24.21) MUTATED AMP PEAK 20(8Q24.21) WILD-TYPE
Number of samples 163 284
'Amp Peak 20(8q24.21) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 1.36e-12 (Fisher's exact test), Q value = 6e-10

Table S50.  Clustering Approach #20: 'Amp Peak 20(8q24.21) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
AMP PEAK 20(8Q24.21) MUTATED 98 8 57
AMP PEAK 20(8Q24.21) WILD-TYPE 252 10 22

Figure S30.  Get High-res Image Clustering Approach #20: 'Amp Peak 20(8q24.21) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #21: 'Amp Peak 21(8q24.21) mutation analysis'

Table S51.  Description of clustering approach #21: 'Amp Peak 21(8q24.21) mutation analysis'

Cluster Labels AMP PEAK 21(8Q24.21) MUTATED AMP PEAK 21(8Q24.21) WILD-TYPE
Number of samples 171 276
'Amp Peak 21(8q24.21) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 1.52e-13 (Fisher's exact test), Q value = 6.8e-11

Table S52.  Clustering Approach #21: 'Amp Peak 21(8q24.21) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
AMP PEAK 21(8Q24.21) MUTATED 104 7 60
AMP PEAK 21(8Q24.21) WILD-TYPE 246 11 19

Figure S31.  Get High-res Image Clustering Approach #21: 'Amp Peak 21(8q24.21) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

'Amp Peak 21(8q24.21) mutation analysis' versus 'COMPLETENESS.OF.RESECTION'

P value = 0.000433 (Fisher's exact test), Q value = 0.15

Table S53.  Clustering Approach #21: 'Amp Peak 21(8q24.21) mutation analysis' versus Clinical Feature #5: 'COMPLETENESS.OF.RESECTION'

nPatients R0 R1 R2 RX
ALL 307 24 15 24
AMP PEAK 21(8Q24.21) MUTATED 115 5 13 10
AMP PEAK 21(8Q24.21) WILD-TYPE 192 19 2 14

Figure S32.  Get High-res Image Clustering Approach #21: 'Amp Peak 21(8q24.21) mutation analysis' versus Clinical Feature #5: 'COMPLETENESS.OF.RESECTION'

Clustering Approach #22: 'Amp Peak 22(9p24.2) mutation analysis'

Table S54.  Description of clustering approach #22: 'Amp Peak 22(9p24.2) mutation analysis'

Cluster Labels AMP PEAK 22(9P24.2) MUTATED AMP PEAK 22(9P24.2) WILD-TYPE
Number of samples 48 399
'Amp Peak 22(9p24.2) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 1.1e-07 (Fisher's exact test), Q value = 4.4e-05

Table S55.  Clustering Approach #22: 'Amp Peak 22(9p24.2) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
AMP PEAK 22(9P24.2) MUTATED 22 2 24
AMP PEAK 22(9P24.2) WILD-TYPE 328 16 55

Figure S33.  Get High-res Image Clustering Approach #22: 'Amp Peak 22(9p24.2) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #23: 'Amp Peak 23(9q34.3) mutation analysis'

Table S56.  Description of clustering approach #23: 'Amp Peak 23(9q34.3) mutation analysis'

Cluster Labels AMP PEAK 23(9Q34.3) MUTATED AMP PEAK 23(9Q34.3) WILD-TYPE
Number of samples 31 416
'Amp Peak 23(9q34.3) mutation analysis' versus 'AGE'

P value = 0.000554 (t-test), Q value = 0.19

Table S57.  Clustering Approach #23: 'Amp Peak 23(9q34.3) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
AMP PEAK 23(9Q34.3) MUTATED 31 69.0 (8.0)
AMP PEAK 23(9Q34.3) WILD-TYPE 415 63.2 (11.4)

Figure S34.  Get High-res Image Clustering Approach #23: 'Amp Peak 23(9q34.3) mutation analysis' versus Clinical Feature #2: 'AGE'

'Amp Peak 23(9q34.3) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 2.26e-07 (Fisher's exact test), Q value = 9e-05

Table S58.  Clustering Approach #23: 'Amp Peak 23(9q34.3) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
AMP PEAK 23(9Q34.3) MUTATED 11 4 16
AMP PEAK 23(9Q34.3) WILD-TYPE 339 14 63

Figure S35.  Get High-res Image Clustering Approach #23: 'Amp Peak 23(9q34.3) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #24: 'Amp Peak 24(10q22.2) mutation analysis'

Table S59.  Description of clustering approach #24: 'Amp Peak 24(10q22.2) mutation analysis'

Cluster Labels AMP PEAK 24(10Q22.2) MUTATED AMP PEAK 24(10Q22.2) WILD-TYPE
Number of samples 121 326
Clustering Approach #25: 'Amp Peak 25(11p11.2) mutation analysis'

Table S60.  Description of clustering approach #25: 'Amp Peak 25(11p11.2) mutation analysis'

Cluster Labels AMP PEAK 25(11P11.2) MUTATED AMP PEAK 25(11P11.2) WILD-TYPE
Number of samples 37 410
'Amp Peak 25(11p11.2) mutation analysis' versus 'AGE'

P value = 0.000241 (t-test), Q value = 0.084

Table S61.  Clustering Approach #25: 'Amp Peak 25(11p11.2) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
AMP PEAK 25(11P11.2) MUTATED 37 69.7 (9.6)
AMP PEAK 25(11P11.2) WILD-TYPE 409 63.0 (11.2)

Figure S36.  Get High-res Image Clustering Approach #25: 'Amp Peak 25(11p11.2) mutation analysis' versus Clinical Feature #2: 'AGE'

'Amp Peak 25(11p11.2) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 5.11e-08 (Fisher's exact test), Q value = 2.1e-05

Table S62.  Clustering Approach #25: 'Amp Peak 25(11p11.2) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
AMP PEAK 25(11P11.2) MUTATED 14 3 20
AMP PEAK 25(11P11.2) WILD-TYPE 336 15 59

Figure S37.  Get High-res Image Clustering Approach #25: 'Amp Peak 25(11p11.2) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #26: 'Amp Peak 26(11q13.2) mutation analysis'

Table S63.  Description of clustering approach #26: 'Amp Peak 26(11q13.2) mutation analysis'

Cluster Labels AMP PEAK 26(11Q13.2) MUTATED AMP PEAK 26(11Q13.2) WILD-TYPE
Number of samples 56 391
'Amp Peak 26(11q13.2) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 2.53e-07 (Fisher's exact test), Q value = 1e-04

Table S64.  Clustering Approach #26: 'Amp Peak 26(11q13.2) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
AMP PEAK 26(11Q13.2) MUTATED 28 2 26
AMP PEAK 26(11Q13.2) WILD-TYPE 322 16 53

Figure S38.  Get High-res Image Clustering Approach #26: 'Amp Peak 26(11q13.2) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #27: 'Amp Peak 27(12p12.1) mutation analysis'

Table S65.  Description of clustering approach #27: 'Amp Peak 27(12p12.1) mutation analysis'

Cluster Labels AMP PEAK 27(12P12.1) MUTATED AMP PEAK 27(12P12.1) WILD-TYPE
Number of samples 67 380
'Amp Peak 27(12p12.1) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 2.77e-07 (Fisher's exact test), Q value = 0.00011

Table S66.  Clustering Approach #27: 'Amp Peak 27(12p12.1) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
AMP PEAK 27(12P12.1) MUTATED 36 2 29
AMP PEAK 27(12P12.1) WILD-TYPE 314 16 50

Figure S39.  Get High-res Image Clustering Approach #27: 'Amp Peak 27(12p12.1) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #28: 'Amp Peak 28(12q13.11) mutation analysis'

Table S67.  Description of clustering approach #28: 'Amp Peak 28(12q13.11) mutation analysis'

Cluster Labels AMP PEAK 28(12Q13.11) MUTATED AMP PEAK 28(12Q13.11) WILD-TYPE
Number of samples 66 381
'Amp Peak 28(12q13.11) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 5.46e-07 (Fisher's exact test), Q value = 0.00021

Table S68.  Clustering Approach #28: 'Amp Peak 28(12q13.11) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
AMP PEAK 28(12Q13.11) MUTATED 35 3 28
AMP PEAK 28(12Q13.11) WILD-TYPE 315 15 51

Figure S40.  Get High-res Image Clustering Approach #28: 'Amp Peak 28(12q13.11) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #29: 'Amp Peak 29(12q13.2) mutation analysis'

Table S69.  Description of clustering approach #29: 'Amp Peak 29(12q13.2) mutation analysis'

Cluster Labels AMP PEAK 29(12Q13.2) MUTATED AMP PEAK 29(12Q13.2) WILD-TYPE
Number of samples 74 373
'Amp Peak 29(12q13.2) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 7.52e-07 (Fisher's exact test), Q value = 0.00029

Table S70.  Clustering Approach #29: 'Amp Peak 29(12q13.2) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
AMP PEAK 29(12Q13.2) MUTATED 41 3 30
AMP PEAK 29(12Q13.2) WILD-TYPE 309 15 49

Figure S41.  Get High-res Image Clustering Approach #29: 'Amp Peak 29(12q13.2) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #30: 'Amp Peak 30(13q34) mutation analysis'

Table S71.  Description of clustering approach #30: 'Amp Peak 30(13q34) mutation analysis'

Cluster Labels AMP PEAK 30(13Q34) MUTATED AMP PEAK 30(13Q34) WILD-TYPE
Number of samples 40 407
'Amp Peak 30(13q34) mutation analysis' versus 'AGE'

P value = 8.08e-07 (t-test), Q value = 0.00032

Table S72.  Clustering Approach #30: 'Amp Peak 30(13q34) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
AMP PEAK 30(13Q34) MUTATED 40 69.9 (7.1)
AMP PEAK 30(13Q34) WILD-TYPE 406 63.0 (11.4)

Figure S42.  Get High-res Image Clustering Approach #30: 'Amp Peak 30(13q34) mutation analysis' versus Clinical Feature #2: 'AGE'

'Amp Peak 30(13q34) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 9.08e-11 (Fisher's exact test), Q value = 3.9e-08

Table S73.  Clustering Approach #30: 'Amp Peak 30(13q34) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
AMP PEAK 30(13Q34) MUTATED 13 3 24
AMP PEAK 30(13Q34) WILD-TYPE 337 15 55

Figure S43.  Get High-res Image Clustering Approach #30: 'Amp Peak 30(13q34) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #31: 'Amp Peak 31(14q24.3) mutation analysis'

Table S74.  Description of clustering approach #31: 'Amp Peak 31(14q24.3) mutation analysis'

Cluster Labels AMP PEAK 31(14Q24.3) MUTATED AMP PEAK 31(14Q24.3) WILD-TYPE
Number of samples 48 399
'Amp Peak 31(14q24.3) mutation analysis' versus 'AGE'

P value = 2.03e-05 (t-test), Q value = 0.0076

Table S75.  Clustering Approach #31: 'Amp Peak 31(14q24.3) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
AMP PEAK 31(14Q24.3) MUTATED 48 69.0 (8.4)
AMP PEAK 31(14Q24.3) WILD-TYPE 398 62.9 (11.4)

Figure S44.  Get High-res Image Clustering Approach #31: 'Amp Peak 31(14q24.3) mutation analysis' versus Clinical Feature #2: 'AGE'

'Amp Peak 31(14q24.3) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 1.62e-11 (Fisher's exact test), Q value = 7e-09

Table S76.  Clustering Approach #31: 'Amp Peak 31(14q24.3) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
AMP PEAK 31(14Q24.3) MUTATED 17 4 27
AMP PEAK 31(14Q24.3) WILD-TYPE 333 14 52

Figure S45.  Get High-res Image Clustering Approach #31: 'Amp Peak 31(14q24.3) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #32: 'Amp Peak 32(14q32.33) mutation analysis'

Table S77.  Description of clustering approach #32: 'Amp Peak 32(14q32.33) mutation analysis'

Cluster Labels AMP PEAK 32(14Q32.33) MUTATED AMP PEAK 32(14Q32.33) WILD-TYPE
Number of samples 57 390
'Amp Peak 32(14q32.33) mutation analysis' versus 'AGE'

P value = 0.000239 (t-test), Q value = 0.084

Table S78.  Clustering Approach #32: 'Amp Peak 32(14q32.33) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
AMP PEAK 32(14Q32.33) MUTATED 57 68.2 (9.4)
AMP PEAK 32(14Q32.33) WILD-TYPE 389 62.9 (11.4)

Figure S46.  Get High-res Image Clustering Approach #32: 'Amp Peak 32(14q32.33) mutation analysis' versus Clinical Feature #2: 'AGE'

'Amp Peak 32(14q32.33) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 1.45e-09 (Fisher's exact test), Q value = 6.1e-07

Table S79.  Clustering Approach #32: 'Amp Peak 32(14q32.33) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
AMP PEAK 32(14Q32.33) MUTATED 25 4 28
AMP PEAK 32(14Q32.33) WILD-TYPE 325 14 51

Figure S47.  Get High-res Image Clustering Approach #32: 'Amp Peak 32(14q32.33) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #33: 'Amp Peak 33(16p11.2) mutation analysis'

Table S80.  Description of clustering approach #33: 'Amp Peak 33(16p11.2) mutation analysis'

Cluster Labels AMP PEAK 33(16P11.2) MUTATED AMP PEAK 33(16P11.2) WILD-TYPE
Number of samples 47 400
'Amp Peak 33(16p11.2) mutation analysis' versus 'AGE'

P value = 0.00031 (t-test), Q value = 0.11

Table S81.  Clustering Approach #33: 'Amp Peak 33(16p11.2) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
AMP PEAK 33(16P11.2) MUTATED 47 68.3 (8.6)
AMP PEAK 33(16P11.2) WILD-TYPE 399 63.0 (11.4)

Figure S48.  Get High-res Image Clustering Approach #33: 'Amp Peak 33(16p11.2) mutation analysis' versus Clinical Feature #2: 'AGE'

'Amp Peak 33(16p11.2) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 8.05e-14 (Fisher's exact test), Q value = 3.6e-11

Table S82.  Clustering Approach #33: 'Amp Peak 33(16p11.2) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
AMP PEAK 33(16P11.2) MUTATED 15 2 30
AMP PEAK 33(16P11.2) WILD-TYPE 335 16 49

Figure S49.  Get High-res Image Clustering Approach #33: 'Amp Peak 33(16p11.2) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #34: 'Amp Peak 34(17q11.2) mutation analysis'

Table S83.  Description of clustering approach #34: 'Amp Peak 34(17q11.2) mutation analysis'

Cluster Labels AMP PEAK 34(17Q11.2) MUTATED AMP PEAK 34(17Q11.2) WILD-TYPE
Number of samples 52 395
'Amp Peak 34(17q11.2) mutation analysis' versus 'AGE'

P value = 0.000251 (t-test), Q value = 0.087

Table S84.  Clustering Approach #34: 'Amp Peak 34(17q11.2) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
AMP PEAK 34(17Q11.2) MUTATED 52 68.0 (8.5)
AMP PEAK 34(17Q11.2) WILD-TYPE 394 63.0 (11.4)

Figure S50.  Get High-res Image Clustering Approach #34: 'Amp Peak 34(17q11.2) mutation analysis' versus Clinical Feature #2: 'AGE'

'Amp Peak 34(17q11.2) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 4.04e-16 (Fisher's exact test), Q value = 1.9e-13

Table S85.  Clustering Approach #34: 'Amp Peak 34(17q11.2) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
AMP PEAK 34(17Q11.2) MUTATED 15 5 32
AMP PEAK 34(17Q11.2) WILD-TYPE 335 13 47

Figure S51.  Get High-res Image Clustering Approach #34: 'Amp Peak 34(17q11.2) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

'Amp Peak 34(17q11.2) mutation analysis' versus 'COMPLETENESS.OF.RESECTION'

P value = 0.000336 (Fisher's exact test), Q value = 0.11

Table S86.  Clustering Approach #34: 'Amp Peak 34(17q11.2) mutation analysis' versus Clinical Feature #5: 'COMPLETENESS.OF.RESECTION'

nPatients R0 R1 R2 RX
ALL 307 24 15 24
AMP PEAK 34(17Q11.2) MUTATED 28 7 6 4
AMP PEAK 34(17Q11.2) WILD-TYPE 279 17 9 20

Figure S52.  Get High-res Image Clustering Approach #34: 'Amp Peak 34(17q11.2) mutation analysis' versus Clinical Feature #5: 'COMPLETENESS.OF.RESECTION'

Clustering Approach #35: 'Amp Peak 35(17q12) mutation analysis'

Table S87.  Description of clustering approach #35: 'Amp Peak 35(17q12) mutation analysis'

Cluster Labels AMP PEAK 35(17Q12) MUTATED AMP PEAK 35(17Q12) WILD-TYPE
Number of samples 53 394
'Amp Peak 35(17q12) mutation analysis' versus 'AGE'

P value = 6.81e-05 (t-test), Q value = 0.025

Table S88.  Clustering Approach #35: 'Amp Peak 35(17q12) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
AMP PEAK 35(17Q12) MUTATED 53 68.8 (9.4)
AMP PEAK 35(17Q12) WILD-TYPE 393 62.9 (11.3)

Figure S53.  Get High-res Image Clustering Approach #35: 'Amp Peak 35(17q12) mutation analysis' versus Clinical Feature #2: 'AGE'

'Amp Peak 35(17q12) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 1.86e-16 (Fisher's exact test), Q value = 8.6e-14

Table S89.  Clustering Approach #35: 'Amp Peak 35(17q12) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
AMP PEAK 35(17Q12) MUTATED 16 3 34
AMP PEAK 35(17Q12) WILD-TYPE 334 15 45

Figure S54.  Get High-res Image Clustering Approach #35: 'Amp Peak 35(17q12) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #36: 'Amp Peak 36(17q25.1) mutation analysis'

Table S90.  Description of clustering approach #36: 'Amp Peak 36(17q25.1) mutation analysis'

Cluster Labels AMP PEAK 36(17Q25.1) MUTATED AMP PEAK 36(17Q25.1) WILD-TYPE
Number of samples 75 372
'Amp Peak 36(17q25.1) mutation analysis' versus 'AGE'

P value = 2.97e-05 (t-test), Q value = 0.011

Table S91.  Clustering Approach #36: 'Amp Peak 36(17q25.1) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
AMP PEAK 36(17Q25.1) MUTATED 75 67.9 (9.0)
AMP PEAK 36(17Q25.1) WILD-TYPE 371 62.7 (11.5)

Figure S55.  Get High-res Image Clustering Approach #36: 'Amp Peak 36(17q25.1) mutation analysis' versus Clinical Feature #2: 'AGE'

'Amp Peak 36(17q25.1) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 2.56e-15 (Fisher's exact test), Q value = 1.2e-12

Table S92.  Clustering Approach #36: 'Amp Peak 36(17q25.1) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
AMP PEAK 36(17Q25.1) MUTATED 30 8 37
AMP PEAK 36(17Q25.1) WILD-TYPE 320 10 42

Figure S56.  Get High-res Image Clustering Approach #36: 'Amp Peak 36(17q25.1) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #37: 'Amp Peak 37(18p11.31) mutation analysis'

Table S93.  Description of clustering approach #37: 'Amp Peak 37(18p11.31) mutation analysis'

Cluster Labels AMP PEAK 37(18P11.31) MUTATED AMP PEAK 37(18P11.31) WILD-TYPE
Number of samples 67 380
'Amp Peak 37(18p11.31) mutation analysis' versus 'AGE'

P value = 0.00028 (t-test), Q value = 0.097

Table S94.  Clustering Approach #37: 'Amp Peak 37(18p11.31) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
AMP PEAK 37(18P11.31) MUTATED 67 67.6 (9.2)
AMP PEAK 37(18P11.31) WILD-TYPE 379 62.9 (11.4)

Figure S57.  Get High-res Image Clustering Approach #37: 'Amp Peak 37(18p11.31) mutation analysis' versus Clinical Feature #2: 'AGE'

'Amp Peak 37(18p11.31) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 2.58e-18 (Fisher's exact test), Q value = 1.2e-15

Table S95.  Clustering Approach #37: 'Amp Peak 37(18p11.31) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
AMP PEAK 37(18P11.31) MUTATED 23 4 40
AMP PEAK 37(18P11.31) WILD-TYPE 327 14 39

Figure S58.  Get High-res Image Clustering Approach #37: 'Amp Peak 37(18p11.31) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #38: 'Amp Peak 38(18q11.2) mutation analysis'

Table S96.  Description of clustering approach #38: 'Amp Peak 38(18q11.2) mutation analysis'

Cluster Labels AMP PEAK 38(18Q11.2) MUTATED AMP PEAK 38(18Q11.2) WILD-TYPE
Number of samples 51 396
'Amp Peak 38(18q11.2) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 8.76e-13 (Fisher's exact test), Q value = 3.9e-10

Table S97.  Clustering Approach #38: 'Amp Peak 38(18q11.2) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
AMP PEAK 38(18Q11.2) MUTATED 18 3 30
AMP PEAK 38(18Q11.2) WILD-TYPE 332 15 49

Figure S59.  Get High-res Image Clustering Approach #38: 'Amp Peak 38(18q11.2) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #39: 'Amp Peak 39(19p13.2) mutation analysis'

Table S98.  Description of clustering approach #39: 'Amp Peak 39(19p13.2) mutation analysis'

Cluster Labels AMP PEAK 39(19P13.2) MUTATED AMP PEAK 39(19P13.2) WILD-TYPE
Number of samples 69 378
'Amp Peak 39(19p13.2) mutation analysis' versus 'AGE'

P value = 4.89e-11 (t-test), Q value = 2.1e-08

Table S99.  Clustering Approach #39: 'Amp Peak 39(19p13.2) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
AMP PEAK 39(19P13.2) MUTATED 69 70.7 (8.4)
AMP PEAK 39(19P13.2) WILD-TYPE 377 62.3 (11.2)

Figure S60.  Get High-res Image Clustering Approach #39: 'Amp Peak 39(19p13.2) mutation analysis' versus Clinical Feature #2: 'AGE'

'Amp Peak 39(19p13.2) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 1.19e-17 (Fisher's exact test), Q value = 5.6e-15

Table S100.  Clustering Approach #39: 'Amp Peak 39(19p13.2) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
AMP PEAK 39(19P13.2) MUTATED 24 7 38
AMP PEAK 39(19P13.2) WILD-TYPE 326 11 41

Figure S61.  Get High-res Image Clustering Approach #39: 'Amp Peak 39(19p13.2) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #40: 'Amp Peak 40(19p13.11) mutation analysis'

Table S101.  Description of clustering approach #40: 'Amp Peak 40(19p13.11) mutation analysis'

Cluster Labels AMP PEAK 40(19P13.11) MUTATED AMP PEAK 40(19P13.11) WILD-TYPE
Number of samples 68 379
'Amp Peak 40(19p13.11) mutation analysis' versus 'AGE'

P value = 1.45e-10 (t-test), Q value = 6.2e-08

Table S102.  Clustering Approach #40: 'Amp Peak 40(19p13.11) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
AMP PEAK 40(19P13.11) MUTATED 68 71.0 (9.0)
AMP PEAK 40(19P13.11) WILD-TYPE 378 62.2 (11.1)

Figure S62.  Get High-res Image Clustering Approach #40: 'Amp Peak 40(19p13.11) mutation analysis' versus Clinical Feature #2: 'AGE'

'Amp Peak 40(19p13.11) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 1.86e-19 (Fisher's exact test), Q value = 8.8e-17

Table S103.  Clustering Approach #40: 'Amp Peak 40(19p13.11) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
AMP PEAK 40(19P13.11) MUTATED 22 6 40
AMP PEAK 40(19P13.11) WILD-TYPE 328 12 39

Figure S63.  Get High-res Image Clustering Approach #40: 'Amp Peak 40(19p13.11) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #41: 'Amp Peak 41(19q12) mutation analysis'

Table S104.  Description of clustering approach #41: 'Amp Peak 41(19q12) mutation analysis'

Cluster Labels AMP PEAK 41(19Q12) MUTATED AMP PEAK 41(19Q12) WILD-TYPE
Number of samples 80 367
'Amp Peak 41(19q12) mutation analysis' versus 'AGE'

P value = 3.71e-10 (t-test), Q value = 1.6e-07

Table S105.  Clustering Approach #41: 'Amp Peak 41(19q12) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
AMP PEAK 41(19Q12) MUTATED 80 69.5 (8.1)
AMP PEAK 41(19Q12) WILD-TYPE 366 62.3 (11.4)

Figure S64.  Get High-res Image Clustering Approach #41: 'Amp Peak 41(19q12) mutation analysis' versus Clinical Feature #2: 'AGE'

'Amp Peak 41(19q12) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 1.93e-34 (Fisher's exact test), Q value = 9.4e-32

Table S106.  Clustering Approach #41: 'Amp Peak 41(19q12) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
AMP PEAK 41(19Q12) MUTATED 18 9 53
AMP PEAK 41(19Q12) WILD-TYPE 332 9 26

Figure S65.  Get High-res Image Clustering Approach #41: 'Amp Peak 41(19q12) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #42: 'Amp Peak 42(20p13) mutation analysis'

Table S107.  Description of clustering approach #42: 'Amp Peak 42(20p13) mutation analysis'

Cluster Labels AMP PEAK 42(20P13) MUTATED AMP PEAK 42(20P13) WILD-TYPE
Number of samples 87 360
'Amp Peak 42(20p13) mutation analysis' versus 'AGE'

P value = 5.29e-05 (t-test), Q value = 0.019

Table S108.  Clustering Approach #42: 'Amp Peak 42(20p13) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
AMP PEAK 42(20P13) MUTATED 87 68.1 (11.2)
AMP PEAK 42(20P13) WILD-TYPE 359 62.5 (11.0)

Figure S66.  Get High-res Image Clustering Approach #42: 'Amp Peak 42(20p13) mutation analysis' versus Clinical Feature #2: 'AGE'

'Amp Peak 42(20p13) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 4.27e-12 (Fisher's exact test), Q value = 1.9e-09

Table S109.  Clustering Approach #42: 'Amp Peak 42(20p13) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
AMP PEAK 42(20P13) MUTATED 43 4 40
AMP PEAK 42(20P13) WILD-TYPE 307 14 39

Figure S67.  Get High-res Image Clustering Approach #42: 'Amp Peak 42(20p13) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #43: 'Amp Peak 43(20q11.21) mutation analysis'

Table S110.  Description of clustering approach #43: 'Amp Peak 43(20q11.21) mutation analysis'

Cluster Labels AMP PEAK 43(20Q11.21) MUTATED AMP PEAK 43(20Q11.21) WILD-TYPE
Number of samples 107 340
'Amp Peak 43(20q11.21) mutation analysis' versus 'AGE'

P value = 3.4e-07 (t-test), Q value = 0.00013

Table S111.  Clustering Approach #43: 'Amp Peak 43(20q11.21) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
AMP PEAK 43(20Q11.21) MUTATED 107 68.2 (10.0)
AMP PEAK 43(20Q11.21) WILD-TYPE 339 62.1 (11.3)

Figure S68.  Get High-res Image Clustering Approach #43: 'Amp Peak 43(20q11.21) mutation analysis' versus Clinical Feature #2: 'AGE'

'Amp Peak 43(20q11.21) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 5.23e-24 (Fisher's exact test), Q value = 2.5e-21

Table S112.  Clustering Approach #43: 'Amp Peak 43(20q11.21) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
AMP PEAK 43(20Q11.21) MUTATED 45 6 56
AMP PEAK 43(20Q11.21) WILD-TYPE 305 12 23

Figure S69.  Get High-res Image Clustering Approach #43: 'Amp Peak 43(20q11.21) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #44: 'Amp Peak 44(20q13.12) mutation analysis'

Table S113.  Description of clustering approach #44: 'Amp Peak 44(20q13.12) mutation analysis'

Cluster Labels AMP PEAK 44(20Q13.12) MUTATED AMP PEAK 44(20Q13.12) WILD-TYPE
Number of samples 112 335
'Amp Peak 44(20q13.12) mutation analysis' versus 'AGE'

P value = 9.91e-08 (t-test), Q value = 4e-05

Table S114.  Clustering Approach #44: 'Amp Peak 44(20q13.12) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
AMP PEAK 44(20Q13.12) MUTATED 112 68.3 (10.3)
AMP PEAK 44(20Q13.12) WILD-TYPE 334 62.0 (11.1)

Figure S70.  Get High-res Image Clustering Approach #44: 'Amp Peak 44(20q13.12) mutation analysis' versus Clinical Feature #2: 'AGE'

'Amp Peak 44(20q13.12) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 1.1e-20 (Fisher's exact test), Q value = 5.3e-18

Table S115.  Clustering Approach #44: 'Amp Peak 44(20q13.12) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
AMP PEAK 44(20Q13.12) MUTATED 51 7 54
AMP PEAK 44(20Q13.12) WILD-TYPE 299 11 25

Figure S71.  Get High-res Image Clustering Approach #44: 'Amp Peak 44(20q13.12) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #45: 'Amp Peak 45(20q13.33) mutation analysis'

Table S116.  Description of clustering approach #45: 'Amp Peak 45(20q13.33) mutation analysis'

Cluster Labels AMP PEAK 45(20Q13.33) MUTATED AMP PEAK 45(20Q13.33) WILD-TYPE
Number of samples 110 337
'Amp Peak 45(20q13.33) mutation analysis' versus 'AGE'

P value = 3.68e-07 (t-test), Q value = 0.00015

Table S117.  Clustering Approach #45: 'Amp Peak 45(20q13.33) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
AMP PEAK 45(20Q13.33) MUTATED 110 68.2 (10.5)
AMP PEAK 45(20Q13.33) WILD-TYPE 336 62.1 (11.1)

Figure S72.  Get High-res Image Clustering Approach #45: 'Amp Peak 45(20q13.33) mutation analysis' versus Clinical Feature #2: 'AGE'

'Amp Peak 45(20q13.33) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 1.61e-16 (Fisher's exact test), Q value = 7.5e-14

Table S118.  Clustering Approach #45: 'Amp Peak 45(20q13.33) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
AMP PEAK 45(20Q13.33) MUTATED 54 6 50
AMP PEAK 45(20Q13.33) WILD-TYPE 296 12 29

Figure S73.  Get High-res Image Clustering Approach #45: 'Amp Peak 45(20q13.33) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #46: 'Amp Peak 46(22q12.2) mutation analysis'

Table S119.  Description of clustering approach #46: 'Amp Peak 46(22q12.2) mutation analysis'

Cluster Labels AMP PEAK 46(22Q12.2) MUTATED AMP PEAK 46(22Q12.2) WILD-TYPE
Number of samples 43 404
'Amp Peak 46(22q12.2) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 5.75e-17 (Fisher's exact test), Q value = 2.7e-14

Table S120.  Clustering Approach #46: 'Amp Peak 46(22q12.2) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
AMP PEAK 46(22Q12.2) MUTATED 10 2 31
AMP PEAK 46(22Q12.2) WILD-TYPE 340 16 48

Figure S74.  Get High-res Image Clustering Approach #46: 'Amp Peak 46(22q12.2) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

'Amp Peak 46(22q12.2) mutation analysis' versus 'COMPLETENESS.OF.RESECTION'

P value = 0.000227 (Fisher's exact test), Q value = 0.08

Table S121.  Clustering Approach #46: 'Amp Peak 46(22q12.2) mutation analysis' versus Clinical Feature #5: 'COMPLETENESS.OF.RESECTION'

nPatients R0 R1 R2 RX
ALL 307 24 15 24
AMP PEAK 46(22Q12.2) MUTATED 23 2 7 4
AMP PEAK 46(22Q12.2) WILD-TYPE 284 22 8 20

Figure S75.  Get High-res Image Clustering Approach #46: 'Amp Peak 46(22q12.2) mutation analysis' versus Clinical Feature #5: 'COMPLETENESS.OF.RESECTION'

Clustering Approach #47: 'Amp Peak 47(Xp11.23) mutation analysis'

Table S122.  Description of clustering approach #47: 'Amp Peak 47(Xp11.23) mutation analysis'

Cluster Labels AMP PEAK 47(XP11.23) MUTATED AMP PEAK 47(XP11.23) WILD-TYPE
Number of samples 72 375
Clustering Approach #48: 'Amp Peak 48(Xq28) mutation analysis'

Table S123.  Description of clustering approach #48: 'Amp Peak 48(Xq28) mutation analysis'

Cluster Labels AMP PEAK 48(XQ28) MUTATED AMP PEAK 48(XQ28) WILD-TYPE
Number of samples 72 375
Clustering Approach #49: 'Del Peak 1(1p36.21) mutation analysis'

Table S124.  Description of clustering approach #49: 'Del Peak 1(1p36.21) mutation analysis'

Cluster Labels DEL PEAK 1(1P36.21) MUTATED DEL PEAK 1(1P36.21) WILD-TYPE
Number of samples 54 393
'Del Peak 1(1p36.21) mutation analysis' versus 'AGE'

P value = 3.28e-05 (t-test), Q value = 0.012

Table S125.  Clustering Approach #49: 'Del Peak 1(1p36.21) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
DEL PEAK 1(1P36.21) MUTATED 54 69.5 (10.3)
DEL PEAK 1(1P36.21) WILD-TYPE 392 62.8 (11.1)

Figure S76.  Get High-res Image Clustering Approach #49: 'Del Peak 1(1p36.21) mutation analysis' versus Clinical Feature #2: 'AGE'

'Del Peak 1(1p36.21) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 1.05e-08 (Fisher's exact test), Q value = 4.4e-06

Table S126.  Clustering Approach #49: 'Del Peak 1(1p36.21) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 1(1P36.21) MUTATED 24 4 26
DEL PEAK 1(1P36.21) WILD-TYPE 326 14 53

Figure S77.  Get High-res Image Clustering Approach #49: 'Del Peak 1(1p36.21) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #50: 'Del Peak 2(1p36.11) mutation analysis'

Table S127.  Description of clustering approach #50: 'Del Peak 2(1p36.11) mutation analysis'

Cluster Labels DEL PEAK 2(1P36.11) MUTATED DEL PEAK 2(1P36.11) WILD-TYPE
Number of samples 59 388
'Del Peak 2(1p36.11) mutation analysis' versus 'AGE'

P value = 3.68e-05 (t-test), Q value = 0.013

Table S128.  Clustering Approach #50: 'Del Peak 2(1p36.11) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
DEL PEAK 2(1P36.11) MUTATED 59 68.8 (9.7)
DEL PEAK 2(1P36.11) WILD-TYPE 387 62.8 (11.3)

Figure S78.  Get High-res Image Clustering Approach #50: 'Del Peak 2(1p36.11) mutation analysis' versus Clinical Feature #2: 'AGE'

'Del Peak 2(1p36.11) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 1.23e-11 (Fisher's exact test), Q value = 5.4e-09

Table S129.  Clustering Approach #50: 'Del Peak 2(1p36.11) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 2(1P36.11) MUTATED 24 4 31
DEL PEAK 2(1P36.11) WILD-TYPE 326 14 48

Figure S79.  Get High-res Image Clustering Approach #50: 'Del Peak 2(1p36.11) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #51: 'Del Peak 3(1q43) mutation analysis'

Table S130.  Description of clustering approach #51: 'Del Peak 3(1q43) mutation analysis'

Cluster Labels DEL PEAK 3(1Q43) MUTATED DEL PEAK 3(1Q43) WILD-TYPE
Number of samples 7 440
Clustering Approach #52: 'Del Peak 4(2p25.3) mutation analysis'

Table S131.  Description of clustering approach #52: 'Del Peak 4(2p25.3) mutation analysis'

Cluster Labels DEL PEAK 4(2P25.3) MUTATED DEL PEAK 4(2P25.3) WILD-TYPE
Number of samples 22 425
Clustering Approach #53: 'Del Peak 5(2q22.1) mutation analysis'

Table S132.  Description of clustering approach #53: 'Del Peak 5(2q22.1) mutation analysis'

Cluster Labels DEL PEAK 5(2Q22.1) MUTATED DEL PEAK 5(2Q22.1) WILD-TYPE
Number of samples 34 413
'Del Peak 5(2q22.1) mutation analysis' versus 'Time to Death'

P value = 9.57e-09 (logrank test), Q value = 4e-06

Table S133.  Clustering Approach #53: 'Del Peak 5(2q22.1) mutation analysis' versus Clinical Feature #1: 'Time to Death'

nPatients nDeath Duration Range (Median), Month
ALL 442 41 0.0 - 187.1 (15.9)
DEL PEAK 5(2Q22.1) MUTATED 34 10 0.1 - 113.2 (7.9)
DEL PEAK 5(2Q22.1) WILD-TYPE 408 31 0.0 - 187.1 (16.7)

Figure S80.  Get High-res Image Clustering Approach #53: 'Del Peak 5(2q22.1) mutation analysis' versus Clinical Feature #1: 'Time to Death'

'Del Peak 5(2q22.1) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 2.41e-05 (Fisher's exact test), Q value = 0.009

Table S134.  Clustering Approach #53: 'Del Peak 5(2q22.1) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 5(2Q22.1) MUTATED 16 1 17
DEL PEAK 5(2Q22.1) WILD-TYPE 334 17 62

Figure S81.  Get High-res Image Clustering Approach #53: 'Del Peak 5(2q22.1) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #54: 'Del Peak 6(2q37.3) mutation analysis'

Table S135.  Description of clustering approach #54: 'Del Peak 6(2q37.3) mutation analysis'

Cluster Labels DEL PEAK 6(2Q37.3) MUTATED DEL PEAK 6(2Q37.3) WILD-TYPE
Number of samples 40 407
Clustering Approach #55: 'Del Peak 7(3p14.2) mutation analysis'

Table S136.  Description of clustering approach #55: 'Del Peak 7(3p14.2) mutation analysis'

Cluster Labels DEL PEAK 7(3P14.2) MUTATED DEL PEAK 7(3P14.2) WILD-TYPE
Number of samples 57 390
'Del Peak 7(3p14.2) mutation analysis' versus 'AGE'

P value = 7.54e-05 (t-test), Q value = 0.027

Table S137.  Clustering Approach #55: 'Del Peak 7(3p14.2) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
DEL PEAK 7(3P14.2) MUTATED 57 67.6 (7.2)
DEL PEAK 7(3P14.2) WILD-TYPE 389 63.0 (11.6)

Figure S82.  Get High-res Image Clustering Approach #55: 'Del Peak 7(3p14.2) mutation analysis' versus Clinical Feature #2: 'AGE'

'Del Peak 7(3p14.2) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 6.23e-15 (Fisher's exact test), Q value = 2.8e-12

Table S138.  Clustering Approach #55: 'Del Peak 7(3p14.2) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 7(3P14.2) MUTATED 19 6 32
DEL PEAK 7(3P14.2) WILD-TYPE 331 12 47

Figure S83.  Get High-res Image Clustering Approach #55: 'Del Peak 7(3p14.2) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #56: 'Del Peak 8(3q13.31) mutation analysis'

Table S139.  Description of clustering approach #56: 'Del Peak 8(3q13.31) mutation analysis'

Cluster Labels DEL PEAK 8(3Q13.31) MUTATED DEL PEAK 8(3Q13.31) WILD-TYPE
Number of samples 21 426
'Del Peak 8(3q13.31) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 6.98e-06 (Fisher's exact test), Q value = 0.0027

Table S140.  Clustering Approach #56: 'Del Peak 8(3q13.31) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 8(3Q13.31) MUTATED 7 1 13
DEL PEAK 8(3Q13.31) WILD-TYPE 343 17 66

Figure S84.  Get High-res Image Clustering Approach #56: 'Del Peak 8(3q13.31) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #57: 'Del Peak 9(4p16.3) mutation analysis'

Table S141.  Description of clustering approach #57: 'Del Peak 9(4p16.3) mutation analysis'

Cluster Labels DEL PEAK 9(4P16.3) MUTATED DEL PEAK 9(4P16.3) WILD-TYPE
Number of samples 66 381
'Del Peak 9(4p16.3) mutation analysis' versus 'AGE'

P value = 0.000139 (t-test), Q value = 0.049

Table S142.  Clustering Approach #57: 'Del Peak 9(4p16.3) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
DEL PEAK 9(4P16.3) MUTATED 66 67.9 (9.2)
DEL PEAK 9(4P16.3) WILD-TYPE 380 62.8 (11.4)

Figure S85.  Get High-res Image Clustering Approach #57: 'Del Peak 9(4p16.3) mutation analysis' versus Clinical Feature #2: 'AGE'

'Del Peak 9(4p16.3) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 2.78e-13 (Fisher's exact test), Q value = 1.2e-10

Table S143.  Clustering Approach #57: 'Del Peak 9(4p16.3) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 9(4P16.3) MUTATED 27 4 35
DEL PEAK 9(4P16.3) WILD-TYPE 323 14 44

Figure S86.  Get High-res Image Clustering Approach #57: 'Del Peak 9(4p16.3) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #58: 'Del Peak 10(4p15.31) mutation analysis'

Table S144.  Description of clustering approach #58: 'Del Peak 10(4p15.31) mutation analysis'

Cluster Labels DEL PEAK 10(4P15.31) MUTATED DEL PEAK 10(4P15.31) WILD-TYPE
Number of samples 66 381
'Del Peak 10(4p15.31) mutation analysis' versus 'AGE'

P value = 8.27e-05 (t-test), Q value = 0.03

Table S145.  Clustering Approach #58: 'Del Peak 10(4p15.31) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
DEL PEAK 10(4P15.31) MUTATED 66 68.1 (9.5)
DEL PEAK 10(4P15.31) WILD-TYPE 380 62.8 (11.4)

Figure S87.  Get High-res Image Clustering Approach #58: 'Del Peak 10(4p15.31) mutation analysis' versus Clinical Feature #2: 'AGE'

'Del Peak 10(4p15.31) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 7.92e-12 (Fisher's exact test), Q value = 3.5e-09

Table S146.  Clustering Approach #58: 'Del Peak 10(4p15.31) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 10(4P15.31) MUTATED 29 3 34
DEL PEAK 10(4P15.31) WILD-TYPE 321 15 45

Figure S88.  Get High-res Image Clustering Approach #58: 'Del Peak 10(4p15.31) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #59: 'Del Peak 11(4q22.1) mutation analysis'

Table S147.  Description of clustering approach #59: 'Del Peak 11(4q22.1) mutation analysis'

Cluster Labels DEL PEAK 11(4Q22.1) MUTATED DEL PEAK 11(4Q22.1) WILD-TYPE
Number of samples 76 371
'Del Peak 11(4q22.1) mutation analysis' versus 'AGE'

P value = 1.58e-05 (t-test), Q value = 0.006

Table S148.  Clustering Approach #59: 'Del Peak 11(4q22.1) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
DEL PEAK 11(4Q22.1) MUTATED 76 68.1 (9.2)
DEL PEAK 11(4Q22.1) WILD-TYPE 370 62.6 (11.4)

Figure S89.  Get High-res Image Clustering Approach #59: 'Del Peak 11(4q22.1) mutation analysis' versus Clinical Feature #2: 'AGE'

'Del Peak 11(4q22.1) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 1.33e-22 (Fisher's exact test), Q value = 6.4e-20

Table S149.  Clustering Approach #59: 'Del Peak 11(4q22.1) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 11(4Q22.1) MUTATED 25 5 46
DEL PEAK 11(4Q22.1) WILD-TYPE 325 13 33

Figure S90.  Get High-res Image Clustering Approach #59: 'Del Peak 11(4q22.1) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #60: 'Del Peak 12(4q34.3) mutation analysis'

Table S150.  Description of clustering approach #60: 'Del Peak 12(4q34.3) mutation analysis'

Cluster Labels DEL PEAK 12(4Q34.3) MUTATED DEL PEAK 12(4Q34.3) WILD-TYPE
Number of samples 91 356
'Del Peak 12(4q34.3) mutation analysis' versus 'AGE'

P value = 1.14e-05 (t-test), Q value = 0.0043

Table S151.  Clustering Approach #60: 'Del Peak 12(4q34.3) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
DEL PEAK 12(4Q34.3) MUTATED 91 67.9 (10.0)
DEL PEAK 12(4Q34.3) WILD-TYPE 355 62.5 (11.3)

Figure S91.  Get High-res Image Clustering Approach #60: 'Del Peak 12(4q34.3) mutation analysis' versus Clinical Feature #2: 'AGE'

'Del Peak 12(4q34.3) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 2.59e-22 (Fisher's exact test), Q value = 1.2e-19

Table S152.  Clustering Approach #60: 'Del Peak 12(4q34.3) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 12(4Q34.3) MUTATED 35 6 50
DEL PEAK 12(4Q34.3) WILD-TYPE 315 12 29

Figure S92.  Get High-res Image Clustering Approach #60: 'Del Peak 12(4q34.3) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #61: 'Del Peak 13(5q11.2) mutation analysis'

Table S153.  Description of clustering approach #61: 'Del Peak 13(5q11.2) mutation analysis'

Cluster Labels DEL PEAK 13(5Q11.2) MUTATED DEL PEAK 13(5Q11.2) WILD-TYPE
Number of samples 78 369
'Del Peak 13(5q11.2) mutation analysis' versus 'AGE'

P value = 6.49e-05 (t-test), Q value = 0.024

Table S154.  Clustering Approach #61: 'Del Peak 13(5q11.2) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
DEL PEAK 13(5Q11.2) MUTATED 78 67.9 (9.8)
DEL PEAK 13(5Q11.2) WILD-TYPE 368 62.7 (11.3)

Figure S93.  Get High-res Image Clustering Approach #61: 'Del Peak 13(5q11.2) mutation analysis' versus Clinical Feature #2: 'AGE'

'Del Peak 13(5q11.2) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 1.47e-21 (Fisher's exact test), Q value = 7e-19

Table S155.  Clustering Approach #61: 'Del Peak 13(5q11.2) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 13(5Q11.2) MUTATED 29 2 47
DEL PEAK 13(5Q11.2) WILD-TYPE 321 16 32

Figure S94.  Get High-res Image Clustering Approach #61: 'Del Peak 13(5q11.2) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #62: 'Del Peak 14(6q26) mutation analysis'

Table S156.  Description of clustering approach #62: 'Del Peak 14(6q26) mutation analysis'

Cluster Labels DEL PEAK 14(6Q26) MUTATED DEL PEAK 14(6Q26) WILD-TYPE
Number of samples 35 412
'Del Peak 14(6q26) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 1.05e-08 (Fisher's exact test), Q value = 4.4e-06

Table S157.  Clustering Approach #62: 'Del Peak 14(6q26) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 14(6Q26) MUTATED 12 3 20
DEL PEAK 14(6Q26) WILD-TYPE 338 15 59

Figure S95.  Get High-res Image Clustering Approach #62: 'Del Peak 14(6q26) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #63: 'Del Peak 15(7p22.3) mutation analysis'

Table S158.  Description of clustering approach #63: 'Del Peak 15(7p22.3) mutation analysis'

Cluster Labels DEL PEAK 15(7P22.3) MUTATED DEL PEAK 15(7P22.3) WILD-TYPE
Number of samples 58 389
'Del Peak 15(7p22.3) mutation analysis' versus 'AGE'

P value = 2.51e-05 (t-test), Q value = 0.0093

Table S159.  Clustering Approach #63: 'Del Peak 15(7p22.3) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
DEL PEAK 15(7P22.3) MUTATED 57 68.9 (9.5)
DEL PEAK 15(7P22.3) WILD-TYPE 389 62.8 (11.3)

Figure S96.  Get High-res Image Clustering Approach #63: 'Del Peak 15(7p22.3) mutation analysis' versus Clinical Feature #2: 'AGE'

'Del Peak 15(7p22.3) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 1.1e-13 (Fisher's exact test), Q value = 4.9e-11

Table S160.  Clustering Approach #63: 'Del Peak 15(7p22.3) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 15(7P22.3) MUTATED 21 5 32
DEL PEAK 15(7P22.3) WILD-TYPE 329 13 47

Figure S97.  Get High-res Image Clustering Approach #63: 'Del Peak 15(7p22.3) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #64: 'Del Peak 16(7q11.22) mutation analysis'

Table S161.  Description of clustering approach #64: 'Del Peak 16(7q11.22) mutation analysis'

Cluster Labels DEL PEAK 16(7Q11.22) MUTATED DEL PEAK 16(7Q11.22) WILD-TYPE
Number of samples 31 416
'Del Peak 16(7q11.22) mutation analysis' versus 'AGE'

P value = 2.09e-05 (t-test), Q value = 0.0078

Table S162.  Clustering Approach #64: 'Del Peak 16(7q11.22) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
DEL PEAK 16(7Q11.22) MUTATED 31 71.0 (8.6)
DEL PEAK 16(7Q11.22) WILD-TYPE 415 63.0 (11.2)

Figure S98.  Get High-res Image Clustering Approach #64: 'Del Peak 16(7q11.22) mutation analysis' versus Clinical Feature #2: 'AGE'

'Del Peak 16(7q11.22) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 9.54e-08 (Fisher's exact test), Q value = 3.9e-05

Table S163.  Clustering Approach #64: 'Del Peak 16(7q11.22) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 16(7Q11.22) MUTATED 11 2 18
DEL PEAK 16(7Q11.22) WILD-TYPE 339 16 61

Figure S99.  Get High-res Image Clustering Approach #64: 'Del Peak 16(7q11.22) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #65: 'Del Peak 17(7q31.1) mutation analysis'

Table S164.  Description of clustering approach #65: 'Del Peak 17(7q31.1) mutation analysis'

Cluster Labels DEL PEAK 17(7Q31.1) MUTATED DEL PEAK 17(7Q31.1) WILD-TYPE
Number of samples 39 408
'Del Peak 17(7q31.1) mutation analysis' versus 'AGE'

P value = 3.68e-06 (t-test), Q value = 0.0014

Table S165.  Clustering Approach #65: 'Del Peak 17(7q31.1) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
DEL PEAK 17(7Q31.1) MUTATED 39 69.9 (7.6)
DEL PEAK 17(7Q31.1) WILD-TYPE 407 63.0 (11.4)

Figure S100.  Get High-res Image Clustering Approach #65: 'Del Peak 17(7q31.1) mutation analysis' versus Clinical Feature #2: 'AGE'

'Del Peak 17(7q31.1) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 4.18e-16 (Fisher's exact test), Q value = 1.9e-13

Table S166.  Clustering Approach #65: 'Del Peak 17(7q31.1) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 17(7Q31.1) MUTATED 8 3 28
DEL PEAK 17(7Q31.1) WILD-TYPE 342 15 51

Figure S101.  Get High-res Image Clustering Approach #65: 'Del Peak 17(7q31.1) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #66: 'Del Peak 18(7q36.3) mutation analysis'

Table S167.  Description of clustering approach #66: 'Del Peak 18(7q36.3) mutation analysis'

Cluster Labels DEL PEAK 18(7Q36.3) MUTATED DEL PEAK 18(7Q36.3) WILD-TYPE
Number of samples 49 398
'Del Peak 18(7q36.3) mutation analysis' versus 'AGE'

P value = 4.14e-08 (t-test), Q value = 1.7e-05

Table S168.  Clustering Approach #66: 'Del Peak 18(7q36.3) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
DEL PEAK 18(7Q36.3) MUTATED 49 70.8 (8.4)
DEL PEAK 18(7Q36.3) WILD-TYPE 397 62.7 (11.3)

Figure S102.  Get High-res Image Clustering Approach #66: 'Del Peak 18(7q36.3) mutation analysis' versus Clinical Feature #2: 'AGE'

'Del Peak 18(7q36.3) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 2.21e-16 (Fisher's exact test), Q value = 1e-13

Table S169.  Clustering Approach #66: 'Del Peak 18(7q36.3) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 18(7Q36.3) MUTATED 13 5 31
DEL PEAK 18(7Q36.3) WILD-TYPE 337 13 48

Figure S103.  Get High-res Image Clustering Approach #66: 'Del Peak 18(7q36.3) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #67: 'Del Peak 19(8p23.2) mutation analysis'

Table S170.  Description of clustering approach #67: 'Del Peak 19(8p23.2) mutation analysis'

Cluster Labels DEL PEAK 19(8P23.2) MUTATED DEL PEAK 19(8P23.2) WILD-TYPE
Number of samples 81 366
'Del Peak 19(8p23.2) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 1.08e-23 (Fisher's exact test), Q value = 5.3e-21

Table S171.  Clustering Approach #67: 'Del Peak 19(8p23.2) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 19(8P23.2) MUTATED 28 4 49
DEL PEAK 19(8P23.2) WILD-TYPE 322 14 30

Figure S104.  Get High-res Image Clustering Approach #67: 'Del Peak 19(8p23.2) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #68: 'Del Peak 20(9p23) mutation analysis'

Table S172.  Description of clustering approach #68: 'Del Peak 20(9p23) mutation analysis'

Cluster Labels DEL PEAK 20(9P23) MUTATED DEL PEAK 20(9P23) WILD-TYPE
Number of samples 51 396
'Del Peak 20(9p23) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 9.61e-11 (Fisher's exact test), Q value = 4.1e-08

Table S173.  Clustering Approach #68: 'Del Peak 20(9p23) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 20(9P23) MUTATED 20 3 28
DEL PEAK 20(9P23) WILD-TYPE 330 15 51

Figure S105.  Get High-res Image Clustering Approach #68: 'Del Peak 20(9p23) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #69: 'Del Peak 21(9q34.11) mutation analysis'

Table S174.  Description of clustering approach #69: 'Del Peak 21(9q34.11) mutation analysis'

Cluster Labels DEL PEAK 21(9Q34.11) MUTATED DEL PEAK 21(9Q34.11) WILD-TYPE
Number of samples 102 345
'Del Peak 21(9q34.11) mutation analysis' versus 'AGE'

P value = 7.77e-10 (t-test), Q value = 3.3e-07

Table S175.  Clustering Approach #69: 'Del Peak 21(9q34.11) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
DEL PEAK 21(9Q34.11) MUTATED 102 68.9 (8.9)
DEL PEAK 21(9Q34.11) WILD-TYPE 344 62.0 (11.4)

Figure S106.  Get High-res Image Clustering Approach #69: 'Del Peak 21(9q34.11) mutation analysis' versus Clinical Feature #2: 'AGE'

'Del Peak 21(9q34.11) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 6.56e-18 (Fisher's exact test), Q value = 3.1e-15

Table S176.  Clustering Approach #69: 'Del Peak 21(9q34.11) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 21(9Q34.11) MUTATED 46 8 48
DEL PEAK 21(9Q34.11) WILD-TYPE 304 10 31

Figure S107.  Get High-res Image Clustering Approach #69: 'Del Peak 21(9q34.11) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #70: 'Del Peak 22(10q23.31) mutation analysis'

Table S177.  Description of clustering approach #70: 'Del Peak 22(10q23.31) mutation analysis'

Cluster Labels DEL PEAK 22(10Q23.31) MUTATED DEL PEAK 22(10Q23.31) WILD-TYPE
Number of samples 53 394
'Del Peak 22(10q23.31) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 1.9e-05 (Fisher's exact test), Q value = 0.0071

Table S178.  Clustering Approach #70: 'Del Peak 22(10q23.31) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 22(10Q23.31) MUTATED 28 3 22
DEL PEAK 22(10Q23.31) WILD-TYPE 322 15 57

Figure S108.  Get High-res Image Clustering Approach #70: 'Del Peak 22(10q23.31) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #71: 'Del Peak 23(11p15.5) mutation analysis'

Table S179.  Description of clustering approach #71: 'Del Peak 23(11p15.5) mutation analysis'

Cluster Labels DEL PEAK 23(11P15.5) MUTATED DEL PEAK 23(11P15.5) WILD-TYPE
Number of samples 78 369
'Del Peak 23(11p15.5) mutation analysis' versus 'AGE'

P value = 3.06e-08 (t-test), Q value = 1.3e-05

Table S180.  Clustering Approach #71: 'Del Peak 23(11p15.5) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
DEL PEAK 23(11P15.5) MUTATED 78 69.2 (8.9)
DEL PEAK 23(11P15.5) WILD-TYPE 368 62.4 (11.3)

Figure S109.  Get High-res Image Clustering Approach #71: 'Del Peak 23(11p15.5) mutation analysis' versus Clinical Feature #2: 'AGE'

'Del Peak 23(11p15.5) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 2.7e-21 (Fisher's exact test), Q value = 1.3e-18

Table S181.  Clustering Approach #71: 'Del Peak 23(11p15.5) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 23(11P15.5) MUTATED 27 6 45
DEL PEAK 23(11P15.5) WILD-TYPE 323 12 34

Figure S110.  Get High-res Image Clustering Approach #71: 'Del Peak 23(11p15.5) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #72: 'Del Peak 24(11q14.1) mutation analysis'

Table S182.  Description of clustering approach #72: 'Del Peak 24(11q14.1) mutation analysis'

Cluster Labels DEL PEAK 24(11Q14.1) MUTATED DEL PEAK 24(11Q14.1) WILD-TYPE
Number of samples 51 396
'Del Peak 24(11q14.1) mutation analysis' versus 'AGE'

P value = 2.66e-05 (t-test), Q value = 0.0098

Table S183.  Clustering Approach #72: 'Del Peak 24(11q14.1) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
DEL PEAK 24(11Q14.1) MUTATED 51 68.9 (8.6)
DEL PEAK 24(11Q14.1) WILD-TYPE 395 62.9 (11.4)

Figure S111.  Get High-res Image Clustering Approach #72: 'Del Peak 24(11q14.1) mutation analysis' versus Clinical Feature #2: 'AGE'

'Del Peak 24(11q14.1) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 3.72e-14 (Fisher's exact test), Q value = 1.7e-11

Table S184.  Clustering Approach #72: 'Del Peak 24(11q14.1) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 24(11Q14.1) MUTATED 16 6 29
DEL PEAK 24(11Q14.1) WILD-TYPE 334 12 50

Figure S112.  Get High-res Image Clustering Approach #72: 'Del Peak 24(11q14.1) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #73: 'Del Peak 25(11q25) mutation analysis'

Table S185.  Description of clustering approach #73: 'Del Peak 25(11q25) mutation analysis'

Cluster Labels DEL PEAK 25(11Q25) MUTATED DEL PEAK 25(11Q25) WILD-TYPE
Number of samples 69 378
'Del Peak 25(11q25) mutation analysis' versus 'AGE'

P value = 0.000158 (t-test), Q value = 0.056

Table S186.  Clustering Approach #73: 'Del Peak 25(11q25) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
DEL PEAK 25(11Q25) MUTATED 69 68.0 (9.9)
DEL PEAK 25(11Q25) WILD-TYPE 377 62.8 (11.3)

Figure S113.  Get High-res Image Clustering Approach #73: 'Del Peak 25(11q25) mutation analysis' versus Clinical Feature #2: 'AGE'

'Del Peak 25(11q25) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 6.29e-15 (Fisher's exact test), Q value = 2.8e-12

Table S187.  Clustering Approach #73: 'Del Peak 25(11q25) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 25(11Q25) MUTATED 27 5 37
DEL PEAK 25(11Q25) WILD-TYPE 323 13 42

Figure S114.  Get High-res Image Clustering Approach #73: 'Del Peak 25(11q25) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #74: 'Del Peak 26(12q23.1) mutation analysis'

Table S188.  Description of clustering approach #74: 'Del Peak 26(12q23.1) mutation analysis'

Cluster Labels DEL PEAK 26(12Q23.1) MUTATED DEL PEAK 26(12Q23.1) WILD-TYPE
Number of samples 34 413
'Del Peak 26(12q23.1) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 4.05e-11 (Fisher's exact test), Q value = 1.7e-08

Table S189.  Clustering Approach #74: 'Del Peak 26(12q23.1) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 26(12Q23.1) MUTATED 10 1 23
DEL PEAK 26(12Q23.1) WILD-TYPE 340 17 56

Figure S115.  Get High-res Image Clustering Approach #74: 'Del Peak 26(12q23.1) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #75: 'Del Peak 27(12q24.33) mutation analysis'

Table S190.  Description of clustering approach #75: 'Del Peak 27(12q24.33) mutation analysis'

Cluster Labels DEL PEAK 27(12Q24.33) MUTATED DEL PEAK 27(12Q24.33) WILD-TYPE
Number of samples 45 402
'Del Peak 27(12q24.33) mutation analysis' versus 'AGE'

P value = 0.000116 (t-test), Q value = 0.041

Table S191.  Clustering Approach #75: 'Del Peak 27(12q24.33) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
DEL PEAK 27(12Q24.33) MUTATED 45 69.0 (9.1)
DEL PEAK 27(12Q24.33) WILD-TYPE 401 63.0 (11.3)

Figure S116.  Get High-res Image Clustering Approach #75: 'Del Peak 27(12q24.33) mutation analysis' versus Clinical Feature #2: 'AGE'

'Del Peak 27(12q24.33) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 4.36e-13 (Fisher's exact test), Q value = 1.9e-10

Table S192.  Clustering Approach #75: 'Del Peak 27(12q24.33) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 27(12Q24.33) MUTATED 15 1 29
DEL PEAK 27(12Q24.33) WILD-TYPE 335 17 50

Figure S117.  Get High-res Image Clustering Approach #75: 'Del Peak 27(12q24.33) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #76: 'Del Peak 28(13q11) mutation analysis'

Table S193.  Description of clustering approach #76: 'Del Peak 28(13q11) mutation analysis'

Cluster Labels DEL PEAK 28(13Q11) MUTATED DEL PEAK 28(13Q11) WILD-TYPE
Number of samples 67 380
'Del Peak 28(13q11) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 7.87e-10 (Fisher's exact test), Q value = 3.3e-07

Table S194.  Clustering Approach #76: 'Del Peak 28(13q11) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 28(13Q11) MUTATED 32 3 32
DEL PEAK 28(13Q11) WILD-TYPE 318 15 47

Figure S118.  Get High-res Image Clustering Approach #76: 'Del Peak 28(13q11) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #77: 'Del Peak 29(13q14.2) mutation analysis'

Table S195.  Description of clustering approach #77: 'Del Peak 29(13q14.2) mutation analysis'

Cluster Labels DEL PEAK 29(13Q14.2) MUTATED DEL PEAK 29(13Q14.2) WILD-TYPE
Number of samples 72 375
'Del Peak 29(13q14.2) mutation analysis' versus 'AGE'

P value = 0.000327 (t-test), Q value = 0.11

Table S196.  Clustering Approach #77: 'Del Peak 29(13q14.2) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
DEL PEAK 29(13Q14.2) MUTATED 72 67.5 (9.6)
DEL PEAK 29(13Q14.2) WILD-TYPE 374 62.8 (11.4)

Figure S119.  Get High-res Image Clustering Approach #77: 'Del Peak 29(13q14.2) mutation analysis' versus Clinical Feature #2: 'AGE'

'Del Peak 29(13q14.2) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 5.28e-05 (Fisher's exact test), Q value = 0.019

Table S197.  Clustering Approach #77: 'Del Peak 29(13q14.2) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 29(13Q14.2) MUTATED 42 4 26
DEL PEAK 29(13Q14.2) WILD-TYPE 308 14 53

Figure S120.  Get High-res Image Clustering Approach #77: 'Del Peak 29(13q14.2) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #78: 'Del Peak 30(14q13.1) mutation analysis'

Table S198.  Description of clustering approach #78: 'Del Peak 30(14q13.1) mutation analysis'

Cluster Labels DEL PEAK 30(14Q13.1) MUTATED DEL PEAK 30(14Q13.1) WILD-TYPE
Number of samples 55 392
'Del Peak 30(14q13.1) mutation analysis' versus 'AGE'

P value = 0.000739 (t-test), Q value = 0.25

Table S199.  Clustering Approach #78: 'Del Peak 30(14q13.1) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
DEL PEAK 30(14Q13.1) MUTATED 55 68.1 (10.0)
DEL PEAK 30(14Q13.1) WILD-TYPE 391 62.9 (11.3)

Figure S121.  Get High-res Image Clustering Approach #78: 'Del Peak 30(14q13.1) mutation analysis' versus Clinical Feature #2: 'AGE'

'Del Peak 30(14q13.1) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 9.68e-12 (Fisher's exact test), Q value = 4.2e-09

Table S200.  Clustering Approach #78: 'Del Peak 30(14q13.1) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 30(14Q13.1) MUTATED 21 5 29
DEL PEAK 30(14Q13.1) WILD-TYPE 329 13 50

Figure S122.  Get High-res Image Clustering Approach #78: 'Del Peak 30(14q13.1) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #79: 'Del Peak 31(15q15.1) mutation analysis'

Table S201.  Description of clustering approach #79: 'Del Peak 31(15q15.1) mutation analysis'

Cluster Labels DEL PEAK 31(15Q15.1) MUTATED DEL PEAK 31(15Q15.1) WILD-TYPE
Number of samples 104 343
'Del Peak 31(15q15.1) mutation analysis' versus 'AGE'

P value = 1.44e-08 (t-test), Q value = 6e-06

Table S202.  Clustering Approach #79: 'Del Peak 31(15q15.1) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
DEL PEAK 31(15Q15.1) MUTATED 104 68.7 (9.6)
DEL PEAK 31(15Q15.1) WILD-TYPE 342 62.0 (11.3)

Figure S123.  Get High-res Image Clustering Approach #79: 'Del Peak 31(15q15.1) mutation analysis' versus Clinical Feature #2: 'AGE'

'Del Peak 31(15q15.1) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 6.83e-21 (Fisher's exact test), Q value = 3.3e-18

Table S203.  Clustering Approach #79: 'Del Peak 31(15q15.1) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 31(15Q15.1) MUTATED 45 7 52
DEL PEAK 31(15Q15.1) WILD-TYPE 305 11 27

Figure S124.  Get High-res Image Clustering Approach #79: 'Del Peak 31(15q15.1) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #80: 'Del Peak 32(15q23) mutation analysis'

Table S204.  Description of clustering approach #80: 'Del Peak 32(15q23) mutation analysis'

Cluster Labels DEL PEAK 32(15Q23) MUTATED DEL PEAK 32(15Q23) WILD-TYPE
Number of samples 83 364
'Del Peak 32(15q23) mutation analysis' versus 'AGE'

P value = 1.79e-05 (t-test), Q value = 0.0067

Table S205.  Clustering Approach #80: 'Del Peak 32(15q23) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
DEL PEAK 32(15Q23) MUTATED 83 67.9 (9.5)
DEL PEAK 32(15Q23) WILD-TYPE 363 62.6 (11.4)

Figure S125.  Get High-res Image Clustering Approach #80: 'Del Peak 32(15q23) mutation analysis' versus Clinical Feature #2: 'AGE'

'Del Peak 32(15q23) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 7.29e-20 (Fisher's exact test), Q value = 3.5e-17

Table S206.  Clustering Approach #80: 'Del Peak 32(15q23) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 32(15Q23) MUTATED 32 5 46
DEL PEAK 32(15Q23) WILD-TYPE 318 13 33

Figure S126.  Get High-res Image Clustering Approach #80: 'Del Peak 32(15q23) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #81: 'Del Peak 33(16p13.3) mutation analysis'

Table S207.  Description of clustering approach #81: 'Del Peak 33(16p13.3) mutation analysis'

Cluster Labels DEL PEAK 33(16P13.3) MUTATED DEL PEAK 33(16P13.3) WILD-TYPE
Number of samples 62 385
'Del Peak 33(16p13.3) mutation analysis' versus 'AGE'

P value = 9.74e-08 (t-test), Q value = 4e-05

Table S208.  Clustering Approach #81: 'Del Peak 33(16p13.3) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
DEL PEAK 33(16P13.3) MUTATED 62 69.3 (8.0)
DEL PEAK 33(16P13.3) WILD-TYPE 384 62.6 (11.4)

Figure S127.  Get High-res Image Clustering Approach #81: 'Del Peak 33(16p13.3) mutation analysis' versus Clinical Feature #2: 'AGE'

'Del Peak 33(16p13.3) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 1.02e-15 (Fisher's exact test), Q value = 4.7e-13

Table S209.  Clustering Approach #81: 'Del Peak 33(16p13.3) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 33(16P13.3) MUTATED 22 4 36
DEL PEAK 33(16P13.3) WILD-TYPE 328 14 43

Figure S128.  Get High-res Image Clustering Approach #81: 'Del Peak 33(16p13.3) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #82: 'Del Peak 34(16q21) mutation analysis'

Table S210.  Description of clustering approach #82: 'Del Peak 34(16q21) mutation analysis'

Cluster Labels DEL PEAK 34(16Q21) MUTATED DEL PEAK 34(16Q21) WILD-TYPE
Number of samples 117 330
'Del Peak 34(16q21) mutation analysis' versus 'AGE'

P value = 7.63e-09 (t-test), Q value = 3.2e-06

Table S211.  Clustering Approach #82: 'Del Peak 34(16q21) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
DEL PEAK 34(16Q21) MUTATED 117 68.2 (9.2)
DEL PEAK 34(16Q21) WILD-TYPE 329 61.9 (11.5)

Figure S129.  Get High-res Image Clustering Approach #82: 'Del Peak 34(16q21) mutation analysis' versus Clinical Feature #2: 'AGE'

'Del Peak 34(16q21) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 1.85e-21 (Fisher's exact test), Q value = 8.9e-19

Table S212.  Clustering Approach #82: 'Del Peak 34(16q21) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 34(16Q21) MUTATED 54 7 56
DEL PEAK 34(16Q21) WILD-TYPE 296 11 23

Figure S130.  Get High-res Image Clustering Approach #82: 'Del Peak 34(16q21) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #83: 'Del Peak 35(16q23.1) mutation analysis'

Table S213.  Description of clustering approach #83: 'Del Peak 35(16q23.1) mutation analysis'

Cluster Labels DEL PEAK 35(16Q23.1) MUTATED DEL PEAK 35(16Q23.1) WILD-TYPE
Number of samples 127 320
'Del Peak 35(16q23.1) mutation analysis' versus 'AGE'

P value = 5.24e-08 (t-test), Q value = 2.1e-05

Table S214.  Clustering Approach #83: 'Del Peak 35(16q23.1) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
DEL PEAK 35(16Q23.1) MUTATED 127 67.8 (9.4)
DEL PEAK 35(16Q23.1) WILD-TYPE 319 61.9 (11.5)

Figure S131.  Get High-res Image Clustering Approach #83: 'Del Peak 35(16q23.1) mutation analysis' versus Clinical Feature #2: 'AGE'

'Del Peak 35(16q23.1) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 3.42e-25 (Fisher's exact test), Q value = 1.7e-22

Table S215.  Clustering Approach #83: 'Del Peak 35(16q23.1) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 35(16Q23.1) MUTATED 59 6 62
DEL PEAK 35(16Q23.1) WILD-TYPE 291 12 17

Figure S132.  Get High-res Image Clustering Approach #83: 'Del Peak 35(16q23.1) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #84: 'Del Peak 36(17p13.3) mutation analysis'

Table S216.  Description of clustering approach #84: 'Del Peak 36(17p13.3) mutation analysis'

Cluster Labels DEL PEAK 36(17P13.3) MUTATED DEL PEAK 36(17P13.3) WILD-TYPE
Number of samples 85 362
'Del Peak 36(17p13.3) mutation analysis' versus 'AGE'

P value = 8.02e-05 (t-test), Q value = 0.029

Table S217.  Clustering Approach #84: 'Del Peak 36(17p13.3) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
DEL PEAK 36(17P13.3) MUTATED 85 67.4 (9.2)
DEL PEAK 36(17P13.3) WILD-TYPE 361 62.7 (11.5)

Figure S133.  Get High-res Image Clustering Approach #84: 'Del Peak 36(17p13.3) mutation analysis' versus Clinical Feature #2: 'AGE'

'Del Peak 36(17p13.3) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 4.59e-17 (Fisher's exact test), Q value = 2.1e-14

Table S218.  Clustering Approach #84: 'Del Peak 36(17p13.3) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 36(17P13.3) MUTATED 35 8 42
DEL PEAK 36(17P13.3) WILD-TYPE 315 10 37

Figure S134.  Get High-res Image Clustering Approach #84: 'Del Peak 36(17p13.3) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #85: 'Del Peak 37(17p12) mutation analysis'

Table S219.  Description of clustering approach #85: 'Del Peak 37(17p12) mutation analysis'

Cluster Labels DEL PEAK 37(17P12) MUTATED DEL PEAK 37(17P12) WILD-TYPE
Number of samples 97 350
'Del Peak 37(17p12) mutation analysis' versus 'AGE'

P value = 1.56e-07 (t-test), Q value = 6.2e-05

Table S220.  Clustering Approach #85: 'Del Peak 37(17p12) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
DEL PEAK 37(17P12) MUTATED 97 68.3 (9.1)
DEL PEAK 37(17P12) WILD-TYPE 349 62.3 (11.5)

Figure S135.  Get High-res Image Clustering Approach #85: 'Del Peak 37(17p12) mutation analysis' versus Clinical Feature #2: 'AGE'

'Del Peak 37(17p12) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 4.91e-24 (Fisher's exact test), Q value = 2.4e-21

Table S221.  Clustering Approach #85: 'Del Peak 37(17p12) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 37(17P12) MUTATED 37 8 52
DEL PEAK 37(17P12) WILD-TYPE 313 10 27

Figure S136.  Get High-res Image Clustering Approach #85: 'Del Peak 37(17p12) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #86: 'Del Peak 38(17p11.2) mutation analysis'

Table S222.  Description of clustering approach #86: 'Del Peak 38(17p11.2) mutation analysis'

Cluster Labels DEL PEAK 38(17P11.2) MUTATED DEL PEAK 38(17P11.2) WILD-TYPE
Number of samples 88 359
'Del Peak 38(17p11.2) mutation analysis' versus 'AGE'

P value = 1.86e-06 (t-test), Q value = 0.00072

Table S223.  Clustering Approach #86: 'Del Peak 38(17p11.2) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
DEL PEAK 38(17P11.2) MUTATED 88 68.2 (9.2)
DEL PEAK 38(17P11.2) WILD-TYPE 358 62.4 (11.4)

Figure S137.  Get High-res Image Clustering Approach #86: 'Del Peak 38(17p11.2) mutation analysis' versus Clinical Feature #2: 'AGE'

'Del Peak 38(17p11.2) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 2.42e-17 (Fisher's exact test), Q value = 1.1e-14

Table S224.  Clustering Approach #86: 'Del Peak 38(17p11.2) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 38(17P11.2) MUTATED 37 7 44
DEL PEAK 38(17P11.2) WILD-TYPE 313 11 35

Figure S138.  Get High-res Image Clustering Approach #86: 'Del Peak 38(17p11.2) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #87: 'Del Peak 39(17q11.2) mutation analysis'

Table S225.  Description of clustering approach #87: 'Del Peak 39(17q11.2) mutation analysis'

Cluster Labels DEL PEAK 39(17Q11.2) MUTATED DEL PEAK 39(17Q11.2) WILD-TYPE
Number of samples 78 369
'Del Peak 39(17q11.2) mutation analysis' versus 'AGE'

P value = 8.22e-06 (t-test), Q value = 0.0031

Table S226.  Clustering Approach #87: 'Del Peak 39(17q11.2) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
DEL PEAK 39(17Q11.2) MUTATED 78 68.2 (9.3)
DEL PEAK 39(17Q11.2) WILD-TYPE 368 62.6 (11.4)

Figure S139.  Get High-res Image Clustering Approach #87: 'Del Peak 39(17q11.2) mutation analysis' versus Clinical Feature #2: 'AGE'

'Del Peak 39(17q11.2) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 1.73e-10 (Fisher's exact test), Q value = 7.4e-08

Table S227.  Clustering Approach #87: 'Del Peak 39(17q11.2) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 39(17Q11.2) MUTATED 38 5 35
DEL PEAK 39(17Q11.2) WILD-TYPE 312 13 44

Figure S140.  Get High-res Image Clustering Approach #87: 'Del Peak 39(17q11.2) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #88: 'Del Peak 40(17q21.2) mutation analysis'

Table S228.  Description of clustering approach #88: 'Del Peak 40(17q21.2) mutation analysis'

Cluster Labels DEL PEAK 40(17Q21.2) MUTATED DEL PEAK 40(17Q21.2) WILD-TYPE
Number of samples 83 364
'Del Peak 40(17q21.2) mutation analysis' versus 'AGE'

P value = 1.11e-05 (t-test), Q value = 0.0042

Table S229.  Clustering Approach #88: 'Del Peak 40(17q21.2) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
DEL PEAK 40(17Q21.2) MUTATED 83 68.1 (9.6)
DEL PEAK 40(17Q21.2) WILD-TYPE 363 62.5 (11.4)

Figure S141.  Get High-res Image Clustering Approach #88: 'Del Peak 40(17q21.2) mutation analysis' versus Clinical Feature #2: 'AGE'

'Del Peak 40(17q21.2) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 4.62e-14 (Fisher's exact test), Q value = 2.1e-11

Table S230.  Clustering Approach #88: 'Del Peak 40(17q21.2) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 40(17Q21.2) MUTATED 37 6 40
DEL PEAK 40(17Q21.2) WILD-TYPE 313 12 39

Figure S142.  Get High-res Image Clustering Approach #88: 'Del Peak 40(17q21.2) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #89: 'Del Peak 41(18q23) mutation analysis'

Table S231.  Description of clustering approach #89: 'Del Peak 41(18q23) mutation analysis'

Cluster Labels DEL PEAK 41(18Q23) MUTATED DEL PEAK 41(18Q23) WILD-TYPE
Number of samples 73 374
'Del Peak 41(18q23) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 1.3e-14 (Fisher's exact test), Q value = 5.9e-12

Table S232.  Clustering Approach #89: 'Del Peak 41(18q23) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 41(18Q23) MUTATED 30 5 38
DEL PEAK 41(18Q23) WILD-TYPE 320 13 41

Figure S143.  Get High-res Image Clustering Approach #89: 'Del Peak 41(18q23) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #90: 'Del Peak 42(19p13.3) mutation analysis'

Table S233.  Description of clustering approach #90: 'Del Peak 42(19p13.3) mutation analysis'

Cluster Labels DEL PEAK 42(19P13.3) MUTATED DEL PEAK 42(19P13.3) WILD-TYPE
Number of samples 116 331
'Del Peak 42(19p13.3) mutation analysis' versus 'AGE'

P value = 1.81e-11 (t-test), Q value = 7.8e-09

Table S234.  Clustering Approach #90: 'Del Peak 42(19p13.3) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
DEL PEAK 42(19P13.3) MUTATED 116 68.9 (8.7)
DEL PEAK 42(19P13.3) WILD-TYPE 330 61.7 (11.5)

Figure S144.  Get High-res Image Clustering Approach #90: 'Del Peak 42(19p13.3) mutation analysis' versus Clinical Feature #2: 'AGE'

'Del Peak 42(19p13.3) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 3.19e-46 (Fisher's exact test), Q value = 1.6e-43

Table S235.  Clustering Approach #90: 'Del Peak 42(19p13.3) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 42(19P13.3) MUTATED 36 8 72
DEL PEAK 42(19P13.3) WILD-TYPE 314 10 7

Figure S145.  Get High-res Image Clustering Approach #90: 'Del Peak 42(19p13.3) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #91: 'Del Peak 43(19p12) mutation analysis'

Table S236.  Description of clustering approach #91: 'Del Peak 43(19p12) mutation analysis'

Cluster Labels DEL PEAK 43(19P12) MUTATED DEL PEAK 43(19P12) WILD-TYPE
Number of samples 38 409
'Del Peak 43(19p12) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 1.35e-07 (Fisher's exact test), Q value = 5.5e-05

Table S237.  Clustering Approach #91: 'Del Peak 43(19p12) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 43(19P12) MUTATED 15 4 19
DEL PEAK 43(19P12) WILD-TYPE 335 14 60

Figure S146.  Get High-res Image Clustering Approach #91: 'Del Peak 43(19p12) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #92: 'Del Peak 44(19q13.43) mutation analysis'

Table S238.  Description of clustering approach #92: 'Del Peak 44(19q13.43) mutation analysis'

Cluster Labels DEL PEAK 44(19Q13.43) MUTATED DEL PEAK 44(19Q13.43) WILD-TYPE
Number of samples 48 399
'Del Peak 44(19q13.43) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 1.08e-14 (Fisher's exact test), Q value = 4.9e-12

Table S239.  Clustering Approach #92: 'Del Peak 44(19q13.43) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 44(19Q13.43) MUTATED 14 4 30
DEL PEAK 44(19Q13.43) WILD-TYPE 336 14 49

Figure S147.  Get High-res Image Clustering Approach #92: 'Del Peak 44(19q13.43) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #93: 'Del Peak 45(20p12.1) mutation analysis'

Table S240.  Description of clustering approach #93: 'Del Peak 45(20p12.1) mutation analysis'

Cluster Labels DEL PEAK 45(20P12.1) MUTATED DEL PEAK 45(20P12.1) WILD-TYPE
Number of samples 25 422
Clustering Approach #94: 'Del Peak 46(22q11.1) mutation analysis'

Table S241.  Description of clustering approach #94: 'Del Peak 46(22q11.1) mutation analysis'

Cluster Labels DEL PEAK 46(22Q11.1) MUTATED DEL PEAK 46(22Q11.1) WILD-TYPE
Number of samples 66 381
'Del Peak 46(22q11.1) mutation analysis' versus 'AGE'

P value = 9.75e-05 (t-test), Q value = 0.035

Table S242.  Clustering Approach #94: 'Del Peak 46(22q11.1) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
DEL PEAK 46(22Q11.1) MUTATED 66 67.8 (8.9)
DEL PEAK 46(22Q11.1) WILD-TYPE 380 62.8 (11.5)

Figure S148.  Get High-res Image Clustering Approach #94: 'Del Peak 46(22q11.1) mutation analysis' versus Clinical Feature #2: 'AGE'

'Del Peak 46(22q11.1) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 1.25e-05 (Fisher's exact test), Q value = 0.0047

Table S243.  Clustering Approach #94: 'Del Peak 46(22q11.1) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 46(22Q11.1) MUTATED 37 3 26
DEL PEAK 46(22Q11.1) WILD-TYPE 313 15 53

Figure S149.  Get High-res Image Clustering Approach #94: 'Del Peak 46(22q11.1) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #95: 'Del Peak 47(22q12.1) mutation analysis'

Table S244.  Description of clustering approach #95: 'Del Peak 47(22q12.1) mutation analysis'

Cluster Labels DEL PEAK 47(22Q12.1) MUTATED DEL PEAK 47(22Q12.1) WILD-TYPE
Number of samples 70 377
'Del Peak 47(22q12.1) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 2.09e-06 (Fisher's exact test), Q value = 0.00081

Table S245.  Clustering Approach #95: 'Del Peak 47(22q12.1) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 47(22Q12.1) MUTATED 38 7 25
DEL PEAK 47(22Q12.1) WILD-TYPE 312 11 54

Figure S150.  Get High-res Image Clustering Approach #95: 'Del Peak 47(22q12.1) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #96: 'Del Peak 48(22q13.31) mutation analysis'

Table S246.  Description of clustering approach #96: 'Del Peak 48(22q13.31) mutation analysis'

Cluster Labels DEL PEAK 48(22Q13.31) MUTATED DEL PEAK 48(22Q13.31) WILD-TYPE
Number of samples 99 348
'Del Peak 48(22q13.31) mutation analysis' versus 'AGE'

P value = 2.37e-08 (t-test), Q value = 9.8e-06

Table S247.  Clustering Approach #96: 'Del Peak 48(22q13.31) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
DEL PEAK 48(22Q13.31) MUTATED 99 68.7 (9.4)
DEL PEAK 48(22Q13.31) WILD-TYPE 347 62.1 (11.3)

Figure S151.  Get High-res Image Clustering Approach #96: 'Del Peak 48(22q13.31) mutation analysis' versus Clinical Feature #2: 'AGE'

'Del Peak 48(22q13.31) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 4.51e-17 (Fisher's exact test), Q value = 2.1e-14

Table S248.  Clustering Approach #96: 'Del Peak 48(22q13.31) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 48(22Q13.31) MUTATED 45 7 47
DEL PEAK 48(22Q13.31) WILD-TYPE 305 11 32

Figure S152.  Get High-res Image Clustering Approach #96: 'Del Peak 48(22q13.31) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #97: 'Del Peak 49(22q13.32) mutation analysis'

Table S249.  Description of clustering approach #97: 'Del Peak 49(22q13.32) mutation analysis'

Cluster Labels DEL PEAK 49(22Q13.32) MUTATED DEL PEAK 49(22Q13.32) WILD-TYPE
Number of samples 105 342
'Del Peak 49(22q13.32) mutation analysis' versus 'AGE'

P value = 5.33e-07 (t-test), Q value = 0.00021

Table S250.  Clustering Approach #97: 'Del Peak 49(22q13.32) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
DEL PEAK 49(22Q13.32) MUTATED 105 68.2 (10.1)
DEL PEAK 49(22Q13.32) WILD-TYPE 341 62.2 (11.2)

Figure S153.  Get High-res Image Clustering Approach #97: 'Del Peak 49(22q13.32) mutation analysis' versus Clinical Feature #2: 'AGE'

'Del Peak 49(22q13.32) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 4.69e-18 (Fisher's exact test), Q value = 2.2e-15

Table S251.  Clustering Approach #97: 'Del Peak 49(22q13.32) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 49(22Q13.32) MUTATED 48 8 49
DEL PEAK 49(22Q13.32) WILD-TYPE 302 10 30

Figure S154.  Get High-res Image Clustering Approach #97: 'Del Peak 49(22q13.32) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Clustering Approach #98: 'Del Peak 50(Xp21.1) mutation analysis'

Table S252.  Description of clustering approach #98: 'Del Peak 50(Xp21.1) mutation analysis'

Cluster Labels DEL PEAK 50(XP21.1) MUTATED DEL PEAK 50(XP21.1) WILD-TYPE
Number of samples 62 385
'Del Peak 50(Xp21.1) mutation analysis' versus 'AGE'

P value = 0.000158 (t-test), Q value = 0.056

Table S253.  Clustering Approach #98: 'Del Peak 50(Xp21.1) mutation analysis' versus Clinical Feature #2: 'AGE'

nPatients Mean (Std.Dev)
ALL 446 63.6 (11.3)
DEL PEAK 50(XP21.1) MUTATED 62 67.8 (8.8)
DEL PEAK 50(XP21.1) WILD-TYPE 384 62.9 (11.5)

Figure S155.  Get High-res Image Clustering Approach #98: 'Del Peak 50(Xp21.1) mutation analysis' versus Clinical Feature #2: 'AGE'

'Del Peak 50(Xp21.1) mutation analysis' versus 'HISTOLOGICAL.TYPE'

P value = 1.32e-12 (Fisher's exact test), Q value = 5.8e-10

Table S254.  Clustering Approach #98: 'Del Peak 50(Xp21.1) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

nPatients ENDOMETRIOID ENDOMETRIAL ADENOCARCINOMA MIXED SEROUS AND ENDOMETRIOID SEROUS ENDOMETRIAL ADENOCARCINOMA
ALL 350 18 79
DEL PEAK 50(XP21.1) MUTATED 26 2 34
DEL PEAK 50(XP21.1) WILD-TYPE 324 16 45

Figure S156.  Get High-res Image Clustering Approach #98: 'Del Peak 50(Xp21.1) mutation analysis' versus Clinical Feature #3: 'HISTOLOGICAL.TYPE'

Methods & Data
Input

  • Cluster data file = all_lesions.conf_99.cnv.cluster.txt

  • Clinical data file = UCEC-TP.clin.merged.picked.txt

  • Number of patients = 447

  • Number of clustering approaches = 98

  • Number of selected clinical features = 5

  • Exclude small clusters that include fewer than K patients, K = 3

Survival analysis

For survival clinical features, the Kaplan-Meier survival curves of tumors with and without gene mutations were plotted and the statistical significance P values were estimated by logrank test (Bland and Altman 2004) using the 'survdiff' function in R

Student's t-test analysis

For continuous numerical clinical features, two-tailed Student's t test with unequal variance (Lehmann and Romano 2005) was applied to compare the clinical values between two tumor subtypes using 't.test' function in R

Fisher's exact test

For binary clinical features, two-tailed Fisher's exact tests (Fisher 1922) were used to estimate the P values using the 'fisher.test' function in R

Q value calculation

For multiple hypothesis correction, Q value is the False Discovery Rate (FDR) analogue of the P value (Benjamini and Hochberg 1995), defined as the minimum FDR at which the test may be called significant. We used the 'Benjamini and Hochberg' method of 'p.adjust' function in R to convert P values into Q values.

Download Results

This is an experimental feature. The full results of the analysis summarized in this report can be downloaded from the TCGA Data Coordination Center.

References
[1] Bland and Altman, Statistics notes: The logrank test, BMJ 328(7447):1073 (2004)
[2] Lehmann and Romano, Testing Statistical Hypotheses (3E ed.), New York: Springer. ISBN 0387988645 (2005)
[3] Fisher, R.A., On the interpretation of chi-square from contingency tables, and the calculation of P, Journal of the Royal Statistical Society 85(1):87-94 (1922)
[4] Benjamini and Hochberg, Controlling the false discovery rate: a practical and powerful approach to multiple testing, Journal of the Royal Statistical Society Series B 59:289-300 (1995)
Copyright © 2013 Broad Institute TCGA GDAC as part of the TCGA Research Network. All rights reserved.
Made with Nozzle